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Abstract 
 
 
Mild platelet-based bleeding disorders are among the most complex bleeding disorders 
to understand, due to the absence of a ‘gold standard’ test for diagnosis and the 
significant overlap with the bleeding phenotype observed in healthy individuals. The 
work in this thesis is focussed on patients with a clinically diagnosed mild platelet 
disorder for which no acquired cause was identified by the referring expert clinician. 
ADP and thromboxane A2 (TxA2) are key secondary mediators of platelet aggregation 
and function in synergy to facilitate robust platelet activation in the event of vascular 
damage. Less than ten function-disrupting inherited gene defects in the ADP P2Y12 
receptor and only one in the platelet TxA2 receptor have been reported, with none in 
the UK. Over a period of nearly 4 years, patients with a diagnosis of platelet 
dysfunction made at UK Comprehensive Haemophilia Care Centres were investigated 
using platelet aggregation and secretion assays alongside controls and reference curves 
to nine platelet agonists to exhibit an abnormal bleeding phenotype in response to 
different platelet agonists, focusing in searching on P2Y12 receptor defects. In addition, 
the P2Y12 ADP receptor from 148 subjects diagnosed with mild type 1 von Willebrand 
Disease (VWD) from the EU MCMDM-1VWD study was sequenced in view of the 
similarity in bleeding phenotype of patients with type 1 VWD and mild platelet 
disorders and the fact that both conditions show  incomplete penetrance consistent with 
a multifactorial basis for each disorder.  The sequencing was performed by Dr Martina 
Daly in Sheffield. The work in this thesis has led to the identification / characterisation 
of a patient who is homozygous for an early nonsense mutation in the P2Y12 ADP 
receptor and two patients with heterozygous point mutations in the P2Y12 ADP 
receptor (who also has type 1VWD) and in the TxA2 receptor. In addition, I studied 
platelet aggregation and secretion, along with a number of more specialised assays, in 
nearly 80 other patients during the course of the thesis and have subdivided these on 
the basis of the observed defect.  Interestingly, in nearly one third of the patients, a 
platelet defect was not found.  
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Chapter 1 – General introduction 
1.1 Platelet physiology 
 
 
1.1.1 Platelet genesis, structure and function 
 
Platelets are small discoid cells of 1–3 µm in diameter and with a mean volume of 7–
11 fl.  They circulate freely in the circulation and under normal circumstances do not 
form strong interactions with each other or to the vessel wall. They are generated in the 
bone marrow from proplatelet arms of their precursor, the megakaryocyte (Hartwig 
and Italiano, 2003), and since they are not created by cell division, they lack a nucleus.  
In humans, platelets have a life span of 8–10 days (Fritz et al., 1986) and this can be 
shorter in other species, such as mouse where the life span is in the order 5–6 days 
(Baker et al., 1997). It is estimated that a single human megakaryocyte can generate 
between 2000–3000 platelets. Platelets are able to synthesise only a very limited 
amount of protein from the low level of cytoplasmic mRNA that is carried over from 
the megakaryocyte. However, it is controversial as to whether this is of physiological 
significance, with the overall consensus being that this is unlikely to play a critical role. 
A constant cycle of megakaryopoiesis is required to maintain the normal plasma 
concentration of platelets of between 1.5–4x108/ml.  A failure to maintain a sufficient 
platelet count, either because of reduced platelet production or increased platelet 
clearance, results in thrombocytopenia which in severe forms is associated with 
prolonged and even spontaneous bleeding.  
 
The platelet has a highly specialised plasma membrane which is rich in a network of 
invaginations known as the open canicular system (OCS) through which exchange 
between the platelet cytoplasm and the surrounding plasma occur. Continuous with the 
OCS lies the dense tubular system which acts as a Ca2+ store and is the site for 
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enzymes that generate endoperoxides and thromboxanes from arachidonic acid. Below 
the plasma membrane is a microtubule ring which gives rise to the discoid shape of the 
non-stimulated resting platelet. The inner leaflet of the platelet plasma membrane 
contains a high level of phosphatidylserine (PS), a negatively charged phospholipid 
which is exposed on the platelet surface upon activation and promotes binding of 
coagulation proteins, a process known as procoagulant activity. The platelet plasma 
membrane is enriched in a wide range of glycoprotein receptors and G protein-coupled 
receptors that enable it to respond rapidly to stimulation and thereby mediate adhesive 
and aggregation events that support the formation of a vascular plug.   
 
The platelet cytoplasm contains three types of secretory granules: dense granules, α-
granules and lysosomes. α- Granules contain a range of proteins, including proteins 
that support thrombus formation e.g. fibrinogen and von Willebrand factor (VWF), 
chemotaxis of leukocytes and haematopoietic stem cells e.g. SDF-1, and which 
facilitate wound repair and support angiogenesis e.g. the growth factors VEGF and 
PDGF. Dense granules contain small molecules and divalent cations, including the 
powerful feedback platelet agonist ADP and the potent vasoconstrictor, serotonin (also 
known as 5-HT). Lysosomes contain a mixture of oxidases and other lytic enzymes, 
which may play a role in the innate defence system although further research is 
required to confirm this (White, 2007). 
 
Vascular damage results in exposure of a network of proteins in the subendothelial 
matrix, including collagen and laminin, which mediate adhesion and powerful 
activation of platelets.  In addition, platelets are activated by thrombin which is 
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generated through the coagulation cascade following exposure of tissue factor which is 
expressed on the surface of exposed and damaged cells. These pathways work together 
in the fight against excessive blood loss into the surrounding tissues following injury, a 
process known as haemostasis. Platelets are therefore critical elements in the 
maintenance of normal haemostasis working in concert with the coagulation cascade 
(Gibbins, 2004). Thrombosis, on the other hand, is an inappropriate haemostatic 
response that leads to a dramatic impediment of blood flow or even occlusion of blood 
vessels. By necessity, the haemostatic process is tightly controlled. Soluble inhibitors 
of coagulation and platelet inhibitors include those released from endothelium, namely 
PGI2 and NO, in addition to those expressed on the endothelial cells like CD39 (the 
ecto-ADPase) (Kaczmarek et al., 1996) which removes ADP (a major platelet feedback 
mediator) and thrombomodulin which converts the procoagulant action of thrombin to 
an anticoagulant action. These limit thrombus growth and serve to prevent activation 
within healthy, intact vessels.  
 
In addition to playing a critical role in haemostasis, platelets play an important role in 
inflammatory responses through release of a number of vasoreactive agents, including 
chemokines and CD40 ligand which facilitate adhesion of leukocytes to endothelial 
cells (Gear and Camerini, 2003). Platelets are also implicated in a number of other 
physiological responses, including liver repair and certain types of angiogenesis. 
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1.1.2 Platelet activation and release of major secondary mediators   
Ordinarily, platelets are unable to interact with each other or with the endothelial cells 
that surround the vessel walls. However, following injury to the vasculature, platelets 
undergo ‘explosive’ activation in order to support the formation of a primary 
haemostatic plug and thereby prevent excessive bleeding. To achieve this, the 
subendothelial matrix proteins, most notably collagen, form a highly reactive surface 
for platelet binding and activation leading to shape change, adhesion, spreading, 
secretion of the major secondary mediators, ADP and TxA2, aggregation and enhanced 
procoagulant activity, which together lead to the formation of a stable platelet-platelet 
aggregate.  These events can be broken down to several defined steps (Watson and 
Harrison, 2005) (Figure 1.1): 
1- Tethering: The participating proteins in this step vary according to the shear force 
in the vessels. Under the intermediate and high shear conditions that are found in 
arteries and arterioles, platelets are recruited to the site of injury through tethering 
to VWF which is immobilised on exposed collagen fibres. The platelet receptor for 
VWF that mediates tethering is the GPIb-IX-V complex, which is a unique receptor 
in the genome that is expressed only in platelets. The critical feature of the 
interaction between VWF and GPIb-IX-V is the very fast on-rate of association 
that enables the tethering to take place.  However, this is not a stable interaction 
due to the fast off-rate of association. In contrast, under the low shear conditions 
that are found in venous system, platelets are able to bind directly to collagen and 
other matrix proteins such as laminin and fibronectin via platelets integrins namely 
α2β1, αIIbβ3, α5β1 and α6β1. 
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2- Platelet activation and stable adhesion: The tethering or capture of platelets 
enables the low affinity immunoglobulin receptor for collagen, GPVI, to mediate 
powerful activation of platelets thereby leading to activation of platelet integrins, 
including α2β1 and αIIbβ3 which promote stable adhesion through binding to 
collagen and VWF, respectively. Platelet activation is also mediated through the 
GPIb-IX-V complex, although this generates a much weaker signal than that of 
GPVI, thereby questioning the physiological significance of this in the context of 
thrombus formation. 
3- Spreading: In order to provide a solid base for the thrombus, platelets undergo a 
dramatic reorganisation of their cytoskeletons leading to formation of filpodia, 
lamellipodia and stress fibres that serve to increase their surface area and 
strengthen their adhesion to the exposed subendothelial matrix and to each other.  
4- Secretion and aggregation: Activated platelets undergo rapid, powerful secretion 
of the contents of the dense and α-granules, and also synthesise thromboxanes from 
released arachidonic acid. ADP & thromboxane A2 (TxA2) are the two major 
feedback mediators that reinforce platelet activation and thereby help to recruit 
further platelets into the growing aggregate. Secretion of the α-granule proteins, 
fibrinogen and VWF, as well as supply of these proteins through the plasma, serves 
to support the growing platelet aggregate by mediating platelet-platelet interactions 
(aggregation) via the major platelet integrin, αIIbβ3, as well as recruitment of further 
platelets through a continued cycle of tethering (via VWF-GPIb-IX-V) and 
activation (via ADP and TxA2). 
5- Thrombus stabilization and clot retraction: The concomitant generation of 
thrombin through clotting serves to further activate platelets, in combination with 
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ADP and TxA2, and also to convert fibrinogen to the insoluble product fibrin 
thereby stabilising the growing thrombus. Stabilisation is further reinforced by the 
process of clot retraction whereby the actin-myosin stress fibres connect to the 
fibrin mesh through integrin αIIbβ3. 
6- Procoagulant activity: The platelets also provide a surface for the generation of 
coagulation factors through exposure of the procoagulant lipid, phosphatidlyserine.  
This therefore generates thrombin at the appropriate site to reinforce platelet 
activation and generate fibrin.  
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1.2 Platelet receptors and their agonists 
The platelet surface is rich in a variety of receptors for a wide range of agonists, 
including G protein-coupled receptors (GPCR), immunoglobulins (Ig), integrins, ion 
channels, cytokine and leucine-rich receptors (Table 1.1). Each of these families of 
receptors is discussed below: 
 
1.2.1 G protein-coupled receptors 
G protein-coupled receptors (GPCRs) are heptahelical transmembrane proteins that 
mediate their effects through activation of heterotrimeric G proteins, consisting of α, β 
and γ subunits.  In order to achieve their differing signalling effects, GPCRs use four 
distinct classes of G protein α-subunits, known as Gαs, Gαi, Gαq and Gα12/13. Receptor 
activation promotes dissociation of GDP from the α-subunit thereby enabling binding 
of GTP. In turn, this causes the α-subunit to dissociate from the βγ-subunits such that it 
is able to bind to effector proteins, including adenylyl cyclase and phospholipase C β 
isoforms (see below). The βγ-subunits also target a number of effector proteins. 
 
1.2.2 Gi family of G protein-coupled receptors 
Gi proteins are so-named because they were originally shown to mediate inhibition of 
adenylyl cyclase, thereby opposing the activation of Gs proteins which stimulates 
formation of cAMP. However, they are now recognised to have a much broader range 
of effector targets, including PI 3-kinase. Platelets express several members of the Gi 
family of G proteins, with Gαi2 and Gαz being the most abundant of this group.  
Platelets also express a low level of Gαi1, although interestingly, a patient has been 
described with a mild bleeding defect attributed to a reduced level of this protein (Patel 
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et al., 2003). The two major Gi-coupled receptors on platelets are the P2Y12 ADP 
receptor and the α2-adrenoceptor, as discussed in further detail below. The unique 
aspect of these two receptors is that neither mediates activation of washed platelets and 
both mediate only partial activation of platelets in platelet rich plasma in the absence of 
feedback mediators. On the other hand, both receptors are able to synergise with Ca2+-
mobilising receptors to mediate powerful platelet activation.  It is this synergy that 
makes ADP such a critical feedback agonist in regulating platelet activation under 
normal physiological circumstances. 
 
1.2.2.1 The P2Y12 ADP receptor 
The P2Y12 ADP receptor is the pharmacological target for clopidogrel, which alongside 
low dose aspirin, is one of the two major antiplatelet drugs used in the long term 
treatment of individuals who are considered to be at risk of thrombosis. However, 
several new P2Y12 receptor antagonists are at an advanced stage of clinical 
development and are therefore likely to replace the use of clopidogrel in the near future, 
which suffers from variability in its effectiveness due to differential metabolism 
between individuals.  Remarkably, clopidogrel was identified before the molecular 
cloning of the P2Y12 receptor, which was achieved independently by two groups for 
human and rat isoforms in 2001 (Hollopeter et al., 2001, Takasaki et al., 2001). The 
human form has 342 amino acid residues and has a classical seven transmembrane 
spanning topography. It has a restricted expression in platelets and subregions of the 
brain (Hollopeter et al., 2001). The gene is located to chromosome 3 and consists of 3 
exons and the coding sequence (1,028 Kb) located entirely within exon 3 (Figure 1.2)  
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The P2Y12 receptor has been shown to be preferentially coupled to Gαi2 but not to Gαz 
in platelets.  This conclusion is based on studies in mutant mice that show Gαi2 is a 
critical component of the signaling pathway for integrin activation by ADP (Jantzen et 
al., 2001). On the other hand, mice deficient in Gαz show impaired platelet activation 
by adrenaline. This has been shown to cause the mice to be more resistant to fatal 
thromboembolism following the injection of collagen together with adrenaline, despite 
the presence of other Gαi family members (Yang et al., 2000).  
 
The mechanism underlying the ability of the P2Y12 receptor to mediate platelet 
activation both on its own and in synergy with other receptors has been extensively 
investigated.  Studies from the Haslam group in the late 1970s (Haslam et al., 1978), 
and more recent studies, have provided strong evidence that inhibition of adenylyl 
cyclase in otherwise non-stimulated platelets, is insufficient to mediate activation, 
thereby focussing attention on other signalling events (Daniel et al., 1999, Lova et al., 
2003, Lova et al., 2002).  A consensus has now emerged that the P2Y12 ADP receptor 
mediates activation through regulation of PI3-kinase and Rap1b (Woulfe et al., 2002, 
Chrzanowska-Wodnicka et al., 2005) although the full sequence of events that underlie 
activation are not yet established (Figure 1.3).  
Mice deficient in P2Y12 show a marked increase in bleeding times (Andre et al., 2003). 
Further, the importance of P2Y12 receptor in mediating platelet activation in 
haemostasis is emphasised by the identification of patients with mild platelet-based 
bleeding disorders that are associated with mutations in the receptor, as discussed in 
further detail in Section 1.4.2.1.    
  21
 
Chapter 1 – General introduction 
 
  22
 
Chapter 1 – General introduction 
 
  23
 
Chapter 1 – General introduction 
 
  24
 
Chapter 1 – General introduction 
1.2.2.2 The α2-adrenoceptor  
 
The α2-adrenoceptor is believed to be the major receptor underlying the activation of 
platelets by adrenaline (Grant and Scrutton, 1979). Historically, the α2-adrenoceptor 
had been proposed to be coupled in platelets to Gαi2  based on studies of adenylyl 
cyclase inhibition in human platelets (Juska and Farndale, 1999, Simonds et al., 1989) , 
however since the generation of Gαz (Yang et al., 2000) and Gαi2 knock out mice 
(Jantzen et al., 2001) it is now recognized that the α2-adrenoceptor is preferentially 
coupled to Gαiz at least in mouse platelets. Adrenaline inhibits cAMP accumulation in 
platelets treated with PGI2 or other activators of adenylyl cyclase, and does not induce 
a detectable calcium response in the absence of additional agonist (Woulfe, 2005). In 
addition, adrenaline stimulates various PI3-K dependent pathways, among them 
activation of Akt and Rap1 (Kim et al., 2004, Woulfe et al., 2002). 
         The physiological role of the α2-adrenoceptor in the activation of human platelets 
is unclear.  There is evidence that a low level of adrenaline is present in platelet dense 
granules and that it is released upon activation thereby raising the possibility that 
adrenaline could be an important feedback agonist. However the general consensus is 
that the P2Y12 ADP receptor is the major feedback receptor activating the Gi family of 
G proteins in platelets, based on studies using P2Y12 receptor-specific antagonists. On 
the other hand, studies in ‘knockout’ mice deficient in the α2-adrenoceptor have 
provided evidence that the adrenoceptor contributes to normal haemostasis, as 
demonstrated by an increase in tail bleeding (Pozgajova et al., 2006). 
 
Further work is needed to fully characterise the molecular basis and the physiological 
role of this receptor in human platelet activation.  
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1.2.3 Gq protein-coupled receptors 
The Gq family of G proteins has two members, Gq and G11, but only the former is 
expressed in platelets (Offermanns et al., 1997). Gq-coupled receptors mediate platelet 
activation through regulation of PLCβ isoforms, thereby generating the second 
messengers inositol 1,4,5-trisphosphate (IP3) and 1,2-diacylglycerol (DAG), which 
mobilise Ca2+ from intracellular stores and activate protein kinase C (PKC), 
respectively. PLCβ2 is the major isoform that is expressed in human platelets, although 
PLCβ3 is also expressed (Lee et al., 1996).  The major Gq-coupled receptors in human 
platelets that play a physiological role in supporting platelet activation are the P2Y1 
ADP receptor, the TxA2 receptor (TP) and the two thrombin receptors, PAR1 and 
PAR4 (Figures 1.3 and 1.4). Mouse platelets, in contrast, do not express PAR1, but 
express PAR3 which facilitates activation of PAR4 by thrombin but does not signal on 
its own. 
 
Many receptors which couple to Gq also couple to the G12/13 family of heterotrimeric G 
proteins, which are also implicated in mediating platelet activation through the p115 
GTP exchange factor, which mediates activation of the small G protein, RhoA.  
Human and mouse platelets are believed to express only the G13 member of this family.  
Studies from the groups of Nieswandt, Offermans and Kunapuli (Nieswandt et al., 
2002, Moers et al., 2003, Moers et al., 2004, Dorsam et al., 2002) using G13-deficient 
mouse platelets and other approaches have demonstrated that this G-protein is able to 
mediate platelet activation downstream of the PAR4 thrombin receptor, although it is 
controversial as to whether it contributes to signalling by the other Gq-coupled 
receptors.    
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1.2.3.1 The P2Y1 ADP receptor 
The P2Y1 Gq-coupled receptor plays a critical role in synergising with the P2Y12 ADP 
receptor in mediating full aggregation of platelets to ADP (Hechler et al., 1998, Savi et 
al., 1998, Jin and Kunapuli, 1998, Gachet, 2006), as is illustrated in the first Results 
Chapter in this thesis (Chapter 3).  Remarkably, this synergy happens despite the 
relatively low level of expression of the P2Y1 receptor, which is in the order of 150 
copies per platelets, thereby emphasising the powerful ability of the P2Y12 receptor to 
synergise with Ca2+-mobilising receptors. Thus, platelet activation by ADP is mediated 
through the combined action of the P2Y1 and the P2Y12 receptors, although of course 
in vivo the P2Y12 receptor is able to synergise with any other Ca2+-mobilising receptor.  
Thus, because of this redundancy, the physiological role of the P2Y1 receptor in 
mediating platelet activation is unclear, and indeed at the present time no patients have 
described with a bleeding defect associated with a defect in this receptor.  On the other 
hand, the ability of the P2Y1 receptor to synergise with the P2Y12 receptor could reflect 
a role in the events that initiate platelet activation following exposure to ADP.  
Moreover, studies in mouse platelets have suggested a potential role of the P2Y1 
receptor in mediating thrombus formation (Leon et al., 1999, Lenain et al., 2003) 
giving rise to the proposal that P2Y1 receptor antagonists may represent a novel class 
of antithrombotics that do not cause bleeding. 
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1.2.3.2 The thromboxane A2 receptor 
Human platelets express a single thromboxane receptor which has been reported to be 
alternatively spliced in the C-terminus to two isoforms, α and β, although the 
significance of this is unclear, and indeed there is evidence that only the TPα form is 
expressed on the platelet surface (Habib et al., 1999).  Both isoforms are encoded by 
the same gene on chromosome 19, which has four exons and gives rise to classical 
seven transmembrane spanning confirmation of 343 amino acids. The coding region 
for the receptor is located in exon 2 and 3 (Nusing et al., 1993) (Figure 1.5).  
 
The thromboxane receptor is activated by TxA2 which is formed from the arachidonic 
acid that is liberated by the action of cytosolic phospholipase A2 (cPLA2).  cPLA2 is 
activated by elevation of intracellular Ca2+ downstream of Gq-coupled and tyrosine 
kinase-linked surface receptors.  The thromboxane receptor mediates powerful platelet 
activation in synergy with the P2Y12 ADP receptor as discussed above, and it is this 
synergy that enables it to play such a powerful role as a feedback receptor controlling 
platelet activation.  Indeed, the critical role of the thromboxane receptor in mediating 
platelet activation is illustrated by the powerful antithrombotic action of low dose 
aspirin, which selectively inhibits platelet cyclooxygenase-1 (COX-1), thereby 
preventing thromboxane formation (platelets unlike most other cells cannot make new 
protein, thereby enabling the use of a reduced aspirin dosage).  Further, a role for the 
thromboxane receptor in haemostasis is indicated by the presence of a significant 
number of patients with mild, platelet-based bleeding defects that are associated with 
an impairment in thromboxane formation, although in all but one of these patients, a 
molecular defect has not been identified (see Chapter 5 for further discussion).  The 
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importance of the thromboxane receptor is further illustrated by the prolonged tail 
bleeding time in ‘knockout’ mice that fail to express the receptor (Thomas et al., 1998).   
 
1.2.3.3 The PAR1 and PAR4 thrombin receptors 
Thrombin is a soluble serine protease which activates two members of the PAR family 
of receptors on human platelets, namely PAR1 and PAR4 and two members on mouse 
platelets, namely PAR3 and PAR4.  Whilst PAR1 and PAR4 are both able to activate 
human platelets, with PAR1 believed to play the major role, only PAR4 is able to 
activate mouse platelets, with the role of PAR3 being to facilitate the interaction of 
thrombin with PAR-4 (Kahn et al., 1998, Xu et al., 1998, Brass, 2003). Thrombin 
cleaves the N-terminal of PAR1 and PAR4, exposing a ‘tethered’ peptide ligand that 
mediates receptor activation.  Significantly, it is possible to mimic the ‘tethered’ ligand 
for each receptor using short thrombin receptor activating peptides (TRAPs) that 
mediates activation of PAR1 or PAR4 without the need for receptor cleavage.  
Moreover, these peptides can be used to activate the platelet in platelet rich plasma, 
whereas the use of thrombin under these conditions generates a platelet-rich clot due to 
cleavage of fibrinogen to fibrin (Coughlin, 2005). Being a very powerful agonist, 
thrombin plays an essential role in activating platelets, just as it does in the formation 
of the fibrin clot. Once ligated, thrombin receptors can activate the heterotrimeric G 
proteins Gq and G13, which regulate PLCβ and Rho kinase, respectively.  
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1.2.4 Glycoprotein receptors  
The platelet membrane is rich in glycoproteins that play a crucial role in the activation 
and aggregation of platelets. Among these is the major signalling receptor for collagen, 
the GPVI-FcR γ-chain complex, the VWF tethering receptor, GPIb-IX-V, and the 
major platelet integrin, αIIbβ3, which is a receptor for a number of adhesion proteins 
including fibrinogen and VWF. 
  
1.2.4.1 Collagen receptors (GPVI and α2β1) 
GPVI was first proposed as a major collagen receptor on platelets in 1987 following 
identification of a patient with a bleeding tendency and an autoimmune 
thrombocytopenia that was brought about by an autoantibody to GPVI and which 
resulted in defective platelet aggregation to collagen. However, it was not for another 
ten years that GPVI became widely recognised as the major signalling receptor for 
collagen following the demonstration of its association with the FcR γ-chain in the 
platelet membrane (Gibbins et al., 1996). The latter contains an immunotyrosine-based 
activation motif (ITAM) that is essential for signalling following clustering of GPVI 
by collagen (Watson and Gibbins, 1998). GPVI was subsequently cloned by the group 
of Clemetson and shown to be a member of the immunoglobulin (Ig) family of surface 
receptors, with two extracellular Ig domains.  The majority of, but not all, studies have 
shown that the level of expression of GPVI is tightly regulated on the platelet surface 
at around 4,000–6,000 copies per platelet (Best et al., 2003, Chen et al., 2002).  
Collagen has a relatively low affinity for GPVI, but its interaction with the 
glycoprotein receptor is facilitated by binding to the other major receptor for collagen 
on the platelet surface, the integrin α2β1 in a process known as the modified two-site, 
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two-step model (Nieswandt and Watson, 2003).  The significance of GPVI in 
mediating platelet activation is illustrated by the increase in bleeding time or 
rebleeding of FcR γ-chain and GPVI deficient mice, respectively, as measured using a 
tail bleeding assay (Kalia et al., 2008, Kato et al., 2003).   
 
Crosslinking of GPVI mediates platelet activation through sequential activation of Src 
and Syk family kinases in a pathway that shares many similarities with those used by 
immune receptors, such as the T- and B-cell antigen receptors.  The critical step in this 
signalling cascade is Src kinase-mediated phosphorylation of the FcR γ-chain ITAM 
enabling binding of Syk through its tandem SH2 domains and initiation of a 
downstream pathway that leads to powerful activation of PLCγ2 (Figure 1.6). The 
integrin α2β1 mediates a much weaker degree of activation of PLCγ2 downstream of 
Src and Syk kinases, but independent of an ITAM.  The synthetic collagen, CRP, 
which consists of a repeat glycine-proline-hydroxyproline sequence, can be used to 
activate GPVI  independent of α2β1 (Jarvis et al., 2002). From the physiological point 
of view, Nieswandt et al have shown that mice injected with GPVI antibody are 
protected from lethal thrombogenic infusions of collagen and adrenaline due to the 
disappearance of GPVI from their platelet surface (Nieswandt et al., 2001) 
emphasizing the importance of the Ig receptor in collagen-induced platelet activation.  
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1.2.4.2 VWF receptor-GPIb-IX-V 
The GPIb-IX-V receptor is one of the most highly expressed of the glycoprotein 
receptors on the platelet surface, with an estimated 25,000 copies per platelet, each 
made up of two subunits of GPIbα, GPIbβ and GPIX and one subunit of GPV.  
However, this stoichiometry has recently been challenged as it was demonstrated that 
Ibα is covalently connected to 2 Ibβ subunits (Luo et al., 2007). As discussed above, 
GPIb-IX-V plays a critical role in mediating tethering of platelets to immobilised VWF 
(via collagen) at intermediate and high rates of shear. Qualitative and quantitative 
defects in the GPIbα, GPIbβ and GPIX components of this receptor give rise to the 
hereditary disorder, Bernard-Soulier syndrome, which is characterised by large 
platelets, thrombocytopenia and severe bleeding. The GPIbα subunit also binds to 
thrombin and, in this way, facilitates its interaction with the PAR1 and PAR4 GPCRs 
described above (De Marco et al., 1994, Jamieson and Okumura, 1978, Dormann et al., 
2000). Binding of VWF to GPIb-IX-V also generates weak intracellular signalling that 
leads to activation of integrin αIIbβ3, although the significance of this is unclear (Savage 
et al., 1996, Yap et al., 2000). 
 
1.2.4.3 The integrin αIIbβ3 
Integrins are heterodimeric proteins consisting of α- and β-subunits. The integrin αIIbβ3 
is the most expressed protein on platelets, where it is present at between 80,000–
120,000 copies per platelet, and is restricted to platelets and megakaryocytes. The 
integrin binds to several adhesion proteins, including VWF and fibrinogen, that 
mediate cross-linking between platelets to form an aggregate. Activation of the integrin 
by surface receptors is known as inside-out signalling, whereas clustering of the 
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integrin by its ligands leads to the generation of outside-in signals that support many 
aspects of platelet activation including spreading.  Patients with mutations or deletions 
in the genes encoding for either of the two subunits exhibit severe bleeding, a condition 
known as Glanzmann Thrombasthenia. A similar condition is seen in mice deficient in 
the αIIb-subunit (Emambokus and Frampton, 2003).  
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1.2.5 Other receptors 
Platelets express many other receptors that have been shown to mediate platelet 
activation, although for many of these their physiological significance is uncertain or 
believed to occur at the level of the megakaryocyte.  Several examples of these are are 
shown below, although the list is not exhaustive: 
i) the low affinity immune receptor FcγRIIA and the C-type lectin receptor, 
CLEC-2, whose endogenous ligand is podoplanin, activate platelets through an ITAM 
or an ITAM-like pathway (Suzuki-Inoue et al., 2007, Fuller et al., 2007).  
ii) platelets express a number of further G protein-coupled receptors, including the 
CXCR4 receptor for SDF-1 which is implicated in the regulation of megakaryocyte 
migration in the bone marrow (Dhanjal et al., 2007). 
iii) the P2X1 receptor is a ligand-gated ion channel for ATP (Mahaut-Smith et al., 
2000).  Activation of P2X1 mediates rapid entry of Ca2+ into the platelet and has been 
proposed to play a critical role in initiating platelet activation.  This receptor undergoes 
rapid desensitization and this has hampered its investigation using washed platelets. 
iv) c-Mpl is a receptor for thrombopoietin, which is recognised as the major 
cytokine regulating the differentiaton and maturation of megakarocytes in the bone 
marrow.  In addition, TPO potentiates the activation of platelets by a wide variety of G 
protein-coupled and tyrosine kinase-linked receptors (Rodriguez-Linares and Watson, 
1994, Rodriguez-Linares and Watson, 1996).    c-Mpl signals through the Janus kinase, 
JAK2, although the mechanism through which it potentiates platelet activation is 
unclear.  Recently, a V617F mutation in JAK2 has been identified in approximately 
50% of patients with essential thrombocythaemia, which is associated with a selective 
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increase in  platelet count (Kralovics et al., 2005, Baxter et al., 2005, Levine et al., 
2005). 
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1.3 Bleeding disorders: acquired and inherited  
Bleeding disorders constitute a wide range of disorders in which the patients tend to 
bleed excessively. Such bleeding may be severe, with bleeding episodes starting in 
early childhood, or mild, discovered after a haemostatic challenge like surgery, dental 
procedures, or trauma. The bleeding symptoms may range from nosebleeds, easy 
bruising or heavy menstrual periods to bleeding into joints, muscles and deep tissues. 
 
In normal healthy individuals, a complex interaction between vessel walls, platelets, 
coagulation and fibrinolytic proteins occurs in order to maintain the blood within the 
vascular compartment in a fluid state or to permit thrombus formation at sites of vessel 
injury. Bleeding disorders occur when any of the above components is abnormal, 
deficient or dysfunctioning and can be either acquired or inherited. Acquired bleeding 
disorders are more frequent than the inherited disorders and range from acquired 
mutations, immune thrombocytopenia, or excessive medication. 
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1.3.1 Coagulation factor defects 
Acquired coagulation factor defects are more frequent than the inherited ones and since 
many coagulation factors are produced in the liver, several of which are vitamin K 
dependent, acquired disorders can be caused by liver disease or vitamin K deficiency. 
Inherited bleeding disorders attributed to ten coagulation factors have been described, 
and tend to be caused by a deficiency or dysfunction of a single or combined 
coagulation factor or clotting component. The most common of these are the 
haemophilias and von Willebrand disease, while others are rare (Laffan and Lee, 2005). 
Haemophilia, is a group of hereditary genetic disorders that historically existed in three 
forms: 
Haemophilia A (classic haemophilia), is the most common sever inherited bleeding 
disorder. It has a sex-linked pattern of inheritance, due to the presence of the gene on 
the X chromosome, with nearly one third resulting from spontaneous mutation. The 
incidence is 30-100/ 106 population. All clinical features of haemophilia A which 
includes recurrent painful joint bleedings and muscle haematomas are due directly or 
indirectly to lack of the clotting Factor VIII. 
Haemophilia B (Christmas disease), is due to Factor IX deficiency. The inheritance 
and clinical features are identical to haemophilia A and the two disorders are normally 
distinguished by specific coagulation factor assays and confirmed by gene sequencing. 
Factor XI deficiency (previously called Haemophilia C) is an autosomally inherited 
condition which is particularly common in Ashkenazi Jews caused by mutations of the 
Factor XI gene on chromosome 4. In comparison with haemophilia A and B, bleeding 
manifestations in FXI deficiency are much less predictable, even in severe deficiency 
and is not related to the FXI level (Bolton-Maggs et al., 2004) 
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.1.3.2 Von Willebrand disease  
Von Willebrand disease (or disorder; VWD) is a bleeding disorder of primary 
haemostasis caused by a complete or partial defect in the concentration, structure, or 
function of von Willebrand factor (VWF).  The estimated prevalence of VWD is 0.8–
1.6 per hundred (Rodeghiero et al., 1987, Werner et al., 1993, Miller CH, 1987) 
making it the most frequent inherited bleeding disorder. The first kindred were 
identified in 1926. The bleeding events that may suggest VWD includes prolonged 
epistaxis, cutaneous haemorrhage and bruising, prolonged bleeding from trivial 
wounds or dental extraction or surgery, in addition to menorrhagia and other mucosal 
bleedings. The disorder is found to have a greater penetrance in female patients due to 
increased haemostatic pressures of menstruation and pregnancy. 
 
In 1994, Sadler (Sadler, 1994) published recommendations for the classification of 
VWD and in 2006 the subcommittee of VWD reevaluated the classification (Sadler et 
al., 2006), which remains primarily clinical, to facilitate the diagnosis, treatment and 
counselling of patients. VWD is classified into three primary categories: Type 1 relates 
to a quantitative partial deficiency, type 2 relates to qualitative defects, and type 3 
relates to a virtually complete deficiency of VWF. Type 2 VWD is further divided into 
four secondary categories. Type 2A includes variants with decreased platelet adhesion 
caused by selective deficiency of high-molecular-weight VWF multimers. Type 2B 
includes variants with increased affinity for platelet glycoprotein Ib. Type 2M includes 
variants with markedly defective platelet adhesion despite a relatively normal size 
distribution of VWF multimers. Type 2N includes variants with markedly reduced 
factor VIII binding capacity.   
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Acquired von Willebrand syndrome is due to an acquired defect in VWF that is 
associated with a variety of underlying disorders or pharmaceutical agents, and result 
in clinical symptoms similar to VWD. Federici et al  (Federici et al., 2000) by using 
data from an international registry showed that  acquired von Willbrand disease was 
usually associated with lymphoproliferative and myeloproliferative disorders, 
neoplasia, immunologic and other miscellaneous conditions. The main mechanisms 
that account for it are circulating autoantibodies to VWF, adsorption of VWF onto 
tumoral or activated cells and proteolytic degradation of VWF. 
 
Von Willebrand disorders that have similar symptoms to bleeding disorders of platelets 
aetiology are described below: 
 
VWD type 1 is defined as an inherited bleeding disorder because of quantitative 
deficiency of VWF. The molecular mechanism in the large majority of type 1 VWD 
cases is unknown. A small number of missense mutations have been reported. In 
classical type 1 VWD , the inheritance is considered to be autosomal dominant and 
linked to the VWF gene (Laffan et al., 2004).   
 
VWD type 2B is usually inherited as an autosomal dominant trait although some 
apparently recessive cases have been described. It results from mutations within the 
anterior region of exon 28, corresponding to the VWF A1 domain, which contains the 
GPIb binding site hence increasing the affinity of this mutant form of VWF for 
spontaneous binding to platelets in vivo, followed by clearance of the VWF and 
platelets. The minimum criteria for diagnosis include a personal or family history of 
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mucosal bleeding and enhancement of platelet aggregation in the presence of low-dose 
of ristocetin and by exclusion of platelet-type, or Pseudo, VWD. 
 
Platelet-type, or Pseudo, VWD: is a rare disorder that is transmitted as an autosomal 
dominant trait and clinically resembles type 2B VWD. It is not due to defects of VWF 
but is caused by mutations in the platelet GPIbα gene, a gain in the functional 
phenotype that increases its affinity for VWF, leading to the binding of the biggest 
VWF multimers which are cleared from the circulation leading to bleeding. Shim K et 
al (Shim et al., 2008) have also reported that an increase in ADAMTS13 cleavage of 
platelet-bound VWF under shear may also contribute to the cause of the disease.  
Platelet size can be increased in platelet-type VWD and may be associated with 
moderate thrombocytopenia (Nurden and Nurden, 2008). The platelet 
hyperresponsiveness may be demonstrated with low concentrations of ristocetin. 
Whereas normal platelets show little or no aggregation at ristocetin concentrations of 
0.5 mg/ml or lower, patient platelets show significant binding of VWF, together with 
strong aggregation (Miller and Castella, 1982).    
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1.3.3 Blood vessel wall disorders 
The vessel wall bleeding disorders are a heterogeneous group characterized by easy 
bruising and spontaneous bleeding from small vessels which manifest in the skin in the 
form of petechiae or ecchymoses or both. The underlying abnormality is either in the 
vessels themselves or in the perivascular connective tissue. These disorders may be 
inherited or acquired. 
 
Hereditary haemorrhagic telangiectasia is an uncommon disorder, transmitted as an 
autosomal dominant trait, presents during childhood with dilated microvascular 
swellings that become more numerous in adult life. The blood moves from the high 
pressurized arteries into the thinner walled veins, bypassing the capillaries, leading to 
arteriovenous malformations known as telangiectases. The extra pressure in these 
vessels, results in compression or irritation of adjacent tissues and frequent episodes of 
severe bleeding (haemorrhage). Nosebleeds are common, however, more serious 
haemorrhages may arise from telangiectasia in such vital organs as the lung, brain or 
the liver. 
 
Acquired vascular defects vary in severity. Some of these defects are due to defective 
vascular supportive tissues especially collagen, as demonstrated by the bruising seen in 
senile purpura, steroid purpura, scurvy, and in the case of simple easy bruising which 
occurs in an otherwise healthy woman of child bearing age. Others are due to 
immunological defects like Henoch schonlein purpura which is a form of an immune 
vasculitis affecting venules in the skin, joints, intestinal mucosa and kidney. 
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Ehlers-Danlos syndrome: a heterogeneous group of inherited connective tissue 
disorders,  the severity of which can vary from mild to life-threatening, is attributed to 
mutations in connective tissue genes which cause defects in collagen and thus, affects 
the skin giving hyperelasticity, joints giving hyperextensibility, and blood vessels 
giving purpura and bruising. The prevalence of each of the six major types that have 
been recognised vary in the population (Laffan and Lee, 2005). 
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1.3.4 Platelet disorders 
Due to the important role of platelets in haemostasis, acquired or inherited 
abnormalities in platelet number or function are associated with a risk of bleeding 
which can range from mild to life threatening. Classically, patients with these disorders 
have signs and symptoms of mucocutaneous bleedings of variable severity, including 
nosebleeds, heavy menstrual bleeding and excessive bleeding after trauma or surgery 
(including dental extractions).  However, it is only patients with the most severe of 
these disorders that are readily identified, with for example the majority of patients 
with Bernard Soulier syndrome or Glanzmann Thrombasthenia being identified soon 
after birth because of characteristic petechiae. On the other hand, patients with mild 
disorders can go undetected for many years until haemostatically challenged e.g. 
through a tooth extraction. 
 
1.3.4.1 Acquired platelet disorders 
In contrast to inherited platelet disorders, which are rare and probably underdiagnosed, 
acquired disorders of platelet function are relatively common in haematology practice 
and can arise through a variety of systemic diseases, medications and procedures. 
Abnormality of platelet function should be considered in patients with mucocutaneous 
bleeding in the absence of thrombocytopenia, von Willebrand disease. Antiplatelet 
agents, including aspirin and clopidogrel, are the most common cause of acquired 
platelet disorders associated with excessive bleeding. In addition, chronic renal failure, 
liver cirrhosis (leading to a reduction in TPO formation), myeloma, the 
myeloproliferative disorders polycythemia vera and essential thrombocythemia (which 
paradoxically is associated with increased thrombosis and increased bleeding) and 
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cardiopulmonary bypass have long been recognized as clinical situations in which 
platelet dysfunction may contribute to bleeding (Hassan and Kroll, 2005).  This group 
of disorders are not the intended focus of the work in this thesis and so, as far as 
possible, we have avoided investigation of patients who fall into this group. 
 
1.3.4.2 Inherited platelet disorders 
Inherited platelet-based bleeding disorders are generally classified according to a 
reduction in platelet count (inherited thrombocytopenias) or function (inherited 
disorders of platelet function), although some disorders are characterized by both 
thrombocytopenia and abnormalities of platelet function.  
 
Inherited Thrombocytopenias (excluding Bernard Soulier syndrome): 
This is a heterogenous group of uncommon conditions that are likely to have been 
misdiagnosed in the past. However due to the recent advances in molecular genetics 
and the widespread use of the electronic cell counters, these conditions are now 
detected with increased frequency and several new entities have been identified.  
Various classifications and investigations have been proposed based on variables like 
platelet size, mode of inheritance and co-existing clinical abnormalities (Balduini et al., 
2002, Drachman, 2004). These include MYH-9- related thrombocytopenia syndromes, 
congenital amegakaryocytic thrombocytopenia, amegakaryocytic thrombocytopenia 
with radioulnar synostosis, X-linked thrombocytopenia with dyserythropoiesis 
(GATA1 mutations) and Wiskott-Aldrich syndrome. The recent review on  behalf of 
the UKHCDO (Bolton-Maggs et al., 2006) highlights the diagnosis and current 
management of each of these specific platelet disorders. 
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Inherited disorders of platelet function: will be discussed thoroughly in Section 1.4.  
 
1.3.5 Diagnosing bleeding disorders: 
History taking is a key part in the assessment of a bleeding disorder and should 
include the site of bleeding, duration of bleeding, precipitating cause and the effects of 
haemostatic challenges such as surgery or childbirth. History of systemic illnesses, 
such as liver or renal failure, and a full drug history should be taken as some widely 
used medications like aspirin can predispose the individual to bleeding and may even 
unmask an underlying lifelong mild bleeding disorder.  A positive family history of 
bleeding disorder can be helpful to the diagnosis, although the absence of a family 
history does not rule out a heritable condition, especially as bleeding is often polygenic. 
 
Clinical Examination: A full general examination should be carried out, carefully 
focusing on the skin, mucous membranes and joints. A mucocutaneous bleeding 
pattern is more common in patients with a primary haemostatic disorder (i.e. platelet 
disorder and von Willebrand disease). On the other hand, deep tissue bleeding, 
haemarthroses and intramuscular haematomas are more common in coagulation 
disorders such as haemophilia. 
 
Investigations: The extent of the investigations used to diagnose the patient is highly 
dependant on the probability of having a bleeding disorder. It is very usual to start with 
a full blood count, blood film and coagulation screen. These tests may be sufficient if 
the history is not strongly suggestive of a bleeding disorder. However, if the bleeding 
history is more convincing then specific assays of coagulation factor and tests of 
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fibrinolysis should be done and if a specific platelet disorder is suspected then platelet 
function tests, platelet flow cytometry and other platelet specialized tests may be 
considered (Greaves M, 2001) which will be explained in details in Section 1.5.  
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1.4 Inherited disorders of platelet function 
The subclassification of inherited disorders in platelet function is challenging since 
many platelet responses are intimately related.  Clear distinction on the grounds of 
altered adhesion, aggregation, secretion and procoagulant activity is in many instances 
problematic (Cattaneo, 2003).  Further, these disorders can give rise to bleeding 
syndromes of varying intensity.  Apart from Bernard-Soulier syndrome, all other 
platelet function defects associated with thrombocytopenia like the MHY-9 related 
thrombocytopenia or Wiskott-Aldrich syndrome will not be discussed in this section. 
 
1.4.1 Severe platelet disorders 
Inherited hemorrhagic manifestations due to platelet function defects were first 
identified in patients with the most severe diseases: 
 
Glanzmann Thrombasthenia, first diagnosed in 1918 (Glanzmann, 1918), is an 
autosomal recessive disease associated with bleeding manifestations that are similar to 
those of patients with Bernard Soulier syndrome, although usually but not necessarily 
of lower severity. The disorder is caused by mutations or deletions in the genes 
encoding for one of the two glycoprotein receptor subunits that form the αIIbβ3 integrin, 
leading either to a reduced level or absence of expression, or a qualitative defect in 
function of one of the subunits. The classical diagnostic criterion of the disease is the 
lack, or severe impairment, of platelet aggregation induced by all agonists, despite a 
normal platelet count.  Platelet clot retraction is also defective and there is an absence 
of fibrinogen in platelet α-granules. In cases associated with the absence of expression 
of the integrin, the condition can be readily diagnosed by flow cytometry using a 
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specific antibody to either subunit.  Conditions associated with normal expression of 
the integrin but defective activation can also be diagnosed in this way using an 
antibody that recognises the active state of αIIbβ3, namely PAC-1.   
 
Bernard-Soulier syndrome (BSS) was first diagnosed in 1948 (Bernard and Soulier, 
1948) and is associated with quantitative or qualitative defects of the platelet 
glycoprotein complex GPIb/IX/V as the result of defects in one of the genes encoding 
GPIbα, GPIbβ or GPIX.  As yet, there are no reports on defects in the gene for GPV 
that have been associated with the disorder.  It is generally considered to have 
autosomal recessive inheritance and is associated with prolonged bleeding, 
thrombocytopenia, giant platelets and decreased platelet survival. It can be readily 
diagnosed as BSS platelets do not agglutinate with ristocetin and this defect is not 
corrected by the addition of normal plasma. 
 
Quebec platelet disorder (QPD) is an autosomal dominant qualitative platelet 
abnormality, with high and possibly complete penetrance (McKay et al., 2004), 
characterized by severe post-traumatic bleeding complications that are unresponsive to 
platelet transfusion.  It is associated with abnormal proteolysis of α-granule proteins, 
severe deficiency of platelet factor V and multimerin, and often but not always a 
reduction in platelet count (Tracy et al., 1984, Hayward et al., 1996).  The genetic 
cause of QPD has recently been linked to the urokinase plasminogen activator gene 
(PLAU) (Diamandis et al., 2009) and so far this syndrome has only been described in 
Canada. 
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1.4.2   Mild platelet disorders 
The concept of mild bleeding disorders has evolved to indicate disorders characterized 
by the presence of more frequent and/or more prominent bleeding symptoms than in 
the normal population. These symptoms usually occur after a recognizable challenge 
and do not usually lead to major discomfort or organ damage, even in the absence of 
medical intervention. The boundary between severe and mild bleeding disorders may 
be considered clinically well defined, but the distinction between normal subjects and 
patients with mild bleeding disorders is often unclear.  For example, the presence of 
‘severe bruising’ or ‘heavy nose bleeds’ is not sufficient to diagnose a mild bleeding 
disorder. It is usually the accumulation of evidence that gives confidence to the belief 
that the patient has a disorder such as, for example, the need for a blood transfusion 
following surgery in association with a history of severe nose bleeds. This can of 
course then be reinforced by demonstration of a defect in platelet function (see analysis 
of platelet function, below).  There have been a surprisingly small number of mutations 
in platelet genes that have been associated with mild bleeding, other than in a few 
specialist cases that are associated with other dysfunctions such as Hermansky-Pudlak 
syndrome (these patients can be more readily identified through the associated 
albinism, visual defects and other symptoms as detailed below) and patients with 
mutations in the RUNX transcription factor (which have an association with acute 
myelogenous Leukaemia) (table 1.2).   
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 1.4.2.1 ADP receptor defects 
So far, no human pathology of the P2Y1 receptor has been reported. On the other hand, 
seven P2Y12 receptor (P2RY12) mutations associated with excessive bleeding have 
been described worldwide to date, with four resulting in a failure to express the 
functional receptor. Homozygous deletions of either 1 or 2 bp in the coding sequence 
caused frameshifts leading to introduction of premature stop codons and a lack of 
demonstrable P2Y12 expression in patients from two families (Cattaneo et al., 1992, 
Cattaneo et al., 2000, Cattaneo, 2003). A further patient was homozygous for a 
missense mutation in the translation initiation codon which resulted in a failure to 
express functional P2Y12 (Shiraga et al., 2005). All patients presented with similar 
lifelong histories of mucosal bleeding, easy bruising, and/or excessive bleeding in 
response to haemostatic challenges, and prolonged bleeding times. Platelets from these 
patients displayed severely impaired ADP-induced aggregation, normal shape change, 
a failure of ADP to inhibit PGE-stimulated adenylyl cyclase and a reduction in the 
number of binding sites for radiolabelled ADP (Cattaneo et al., 1992, Cattaneo et al., 
2000, Shiraga et al., 2005). A heterozygous carrier of one of the null alleles described 
above, on the other hand, had a mildly prolonged bleeding time, and platelets which 
showed only moderate reductions in platelet ADP binding sites, and in adenylyl 
cyclase inhibition by ADP (Cattaneo et al., 2000). Moreover, the platelets showed a 
normal aggregation response to high concentrations of ADP (20µM), but reduced and 
reversible aggregation to 4 µM ADP, as well as impaired or borderline low ATP 
secretion in response to a range of agonists (Cattaneo et al., 2000). Another patient was 
heterozygous for a mutated allele which had a 2 bp deletion in the coding region 
causing a frameshift and introduction of a premature stop codon (Hollopeter et al., 
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2001). Although the second allele appeared to have a normal coding sequence, the 
patient’s platelets demonstrated a complete absence of P2Y12 receptors and platelet 
RNA analysis revealed the presence of P2RY12 transcripts derived only from the 
mutated allele. Platelets from the daughter of this patient, who had one wild-type allele, 
and one frame-shifted allele, displayed a moderate reduction in ADP binding sites, and 
impaired ADP-dependent aggregation at low concentrations of ADP (Hollopeter et al., 
2001).  
 
A naturally occurring mutation that resulted in expression of dysfunctional P2Y12 
receptors was identified in a patient with a lifelong history of easy bruising and 
excessive blood loss in response to surgery and trauma who was compound 
heterozygous for two mutations predicting substitution of arginine residues 256 and 
265 by glutamine and tryptophan, respectively (Cattaneo et al., 2003). Platelets from 
this patient shape changed normally, but demonstrated reduced aggregation in response 
to a high concentration of 20 µM ADP, although the fact that a response is observed 
demonstrates that either one or possibly both mutations gives rise to impairment rather 
than abolition of function. The R256Q and R265W variants supported normal binding 
to [3H]2MeS-ADP suggesting a failure in receptor function downstream of agonist 
interaction (Cattaneo et al., 2003). 
 
Recently, a patient with a haemorrhagic diathesis and a heterozygous P2RY12 
mutation (P258T) has been described, whose platelets failed to aggregate in response 
to low concentrations of ADP (≤4 µM), but showed reduced and reversible aggregation 
at higher concentrations of ADP (20 µM) (Remijn et al., 2007).  
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1.4.2.2 Thromboxane A2  pathway  
Many clinics have reported patients with defective platelet aggregation to arachidonic 
acid and in many cases the patients have been suspected to be under the influence of 
COX inhibitor. Indeed, there has only been one genetic defect identified which was a 
defect in TP receptor. Hirata et al (Hirata et al., 1994) described a defective platelet 
aggregation to TxA2 in several unrelated Japanese patients giving rise to an inherited 
bleeding disorder. An alteration in the gene product was suggested and linked to an 
Arg60 to Leu substitution in the first cytoplasmic loop of the TxA2 receptor. 
Aggregation responses to several agonists were impaired with the exception of 
thrombin. Ushikubi et al and Fuse et al studied the binding and GTPase activity of 
TxA2 analogues to these platelets and suggested that the defect was in TxA2 receptor 
G-protein coupling. (Ushikubi et al., 1987, Ushikubi et al., 1992, Fuse et al., 1993).  
 
Recently,  one publication has shown an inherited human cPLA2α deficiency which is 
associated with impaired eicosanoid biosynthesis, small intestinal ulceration and 
platelet dysfunction but not to defective platelet aggregation to arachidonic acid (Adler 
et al., 2008). 
 
No mutations have yet been identified in the gene encoding the cyclooxygenase 
enzyme, in spite of descriptions of many patients with COX inhibition like defects, 
which may be partly due to the challenge in sequencing the large genomic COX gene.         
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1.4.2.3 Platelet secretion defect (storage pool disease)   
This is a heterogeneous group of disorders which most likely represent the largest 
group of platelet function disorders, resulting from a deficiency of granules (α or δ or 
both) or defective release of granules upon platelet activation.  
 
δ- storage pool deficiency:  
Dense granule (δ) storage pool disorders can appear as a singular clinical disease or as 
part of other hereditary disorders of lysosome-related organelles such as Hermansky-
Pudlack and Chediak-Higashi syndrome. Lumiaggregometry is a helpful diagnostic 
tool in dense granule disorders  in addition to electron microscopy.  
 
Hermansky Pudlak syndrome (HPS) first described in 1959 (Hermansky and Pudlak, 
1959), is a rare heterogeneous disorder of variable severity inherited in an autosomal 
recessive manner. It is more common in some areas of the world, most notably Puerto 
Rico, where it is the most common form of recessive disorder. It is caused by defects 
in proteins involved in intracellular vesicle trafficking and the biogenesis of lysosome-
related organelles, specifically melanosomes and platelet dense granules. 
Eight mutations in human genes have been identified in HPS. These are HPS1, 
AP3B1/HPS2, HPS3, HPS4, HPS5, HPS6, HPS-7/DTNBP1 (Di Pietro and 
Dell'Angelica, 2005) and HPS8 (Morgan et al., 2006). An additional nine other genes 
have been identified in mouse models of HPS, but counterparts have not yet been 
described in humans. The usual manifestations in all forms of HPS are oculocutaneous 
albinism and prolonged bleeding, however, additional manifestations like pulmonary 
fibrosis and immunodeficiency are characteristics of mutations in specific HPS genes. 
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The bleeding diathesis is due to a storage pool deficiency caused by the lack of platelet 
dense granules leading to impaired platelet aggregation and secretion induced by 
several platelet agonists. 
 
Chediak-Higashi syndrome (CHS) is an autosomal recessive disorder affecting 
haemopoetic (platelets and neutrophils) and non haemopoietic cells, and which in 
common with HPS, is associated with oculocutaneous albinism and a platelet dense 
granule disorder, in addition to recurrent infections due to impaired bacteriocidal 
activity. Death usually occurs in childhood (Cattaneo, 2003). The CHS gene encodes a 
large protein, CHS1/LYST, that functions in lipid-related protein trafficking. Several 
mutations throughout this gene have been described upon which the prediction of the 
severity of the disease depends. 
 
α- granule defects  
The defects result from deficiency of proteins which are synthesized in 
megakaryocytes or endocytosed from plasma and stored in the α-granules. These 
include conditions like:  
 
Gray platelet syndrome: in which platelets appears gray on peripheral blood smears 
treated with Wright–Giemsa stain due to the lack of α-granules and their constituents. 
Patients may have thrombocytopenia in addition. The molecular basis of this syndrome 
is still not clear, however more than one gene may be involved as both autosomal 
recessive and autosomal dominant patterns of inheritance have been described. 
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Paris-Trousseau-Jacobsen syndrome: is a rare syndrome in which the patient is 
presented with multiple congenital abnormalities, mental retardation and mild bleeding 
tendency. Giant α-granules with or without thrombocytopenia are present. This 
syndrome is inherited in an autosomal dominant manner due to deletions in 
chromosome 11q that including the FLI1 gene, which encodes a transcription factor 
that is essential for megakaryopoiesis hence giving the characteristic appearance of two 
morphologically distinct populations of megakaryocytes in the bone marrow (Raslova 
et al., 2004).  
 
Quebec platelet disorder: (mentioned under severe platelet disorders in section 1.4.1). 
 
ARC syndrome: (arythrogryposis-renal dysfunction and cholestasis) a multisystemic 
disorder in which affected babies suffer from impairment to kidney and liver function, 
bleeding problems and weak muscles. It is inherited as an autosomal recessive disorder 
due to a mutation in the gene VPS33B, which encodes for a protein that is involved in 
protein trafficking (Gissen et al., 2004, Lo et al., 2005). 
 
The above four conditions are unique to the α-granule pool while other disorders may 
be associated with inherited deficiencies of the corresponding plasma proteins e.g. 
fibrinogen in afibrinogenaemia. 
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α , δ - storage pool deficiency:  
Weiss et al have described a storage pool deficiency where both α and δ granules are 
deficient (Weiss et al., 1979, Weiss et al., 1993). This deficiency shows the same 
platelet aggregation abnormalities and clinical picture to δ - storage pool deficiency. 
 
  60
 
Chapter 1 – General introduction 
1.4.2.4 Other receptor defects 
 
GPVI: Two patients with a congenital GPVI deficiency have been reported. Both 
patients are compound heterozygotes (Dumont et al., 2009, Hermans et al., 2009). The 
first patient is a 10 yr old girl presented with ecchymoses since infancy and a 
prolonged bleeding time. The patient's platelets failed to respond to collagen up to 4 
μg/mL but aggregated normally in response to ADP, TRAP, arachidonic acid and 
ristocetin. GPVI DNA sequencing revealed a R38C mutation in exon 3 of one allele 
and an insertion of 5 nucleotides in exon 4 of the other allele  giving rise to a base-shift 
(Dumont et al., 2009). The second patient has a lifelong history of bleeding problems 
and was found to be a compound heterozygous for a 16 bp deletion and a missense 
mutation S175N of GPVI (Hermans et al., 2009).  Subsequent studies demonstrated 
that the R38C and S175N mutations give rise to non-functional forms of GPVI. 
In addition, several patients with autoimmune thrombocytopenia, who are deficient in 
GPVI receptors and whose platelets are unresponsive to collagen have been reported 
(Sugiyama et al., 1987, Moroi and Jung, 1997, Kojima et al., 2006). All of these 
patients have shown a mild bleeding tendency.  
 
α2- adrenoceptor: Tamponi et al (Tamponi et al., 1987) have described two patients 
(mother and son) where a decreased platelet response to adrenaline was found to be 
associated with a congenital defect in the platelet α2 adrenergic  receptors. Another 
family in which several members had a history of easy bruising and minimal 
prolongation  of  bleeding times has also been described and found to have impaired 
aggregation and secretion in response to adrenaline in association with a decreased 
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number of platelet α2- adrenoceptors (Rao et al., 1988). However, the diagnosis was 
based on radioligand binding experiments and needs to be verified genetically. 
 
PAR1 & PAR4: No human pathology has so far been described in relation to the two 
thrombin receptors PAR1 & PAR4.  
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1.4.2.5 Signal transduction defects 
Platelet disorders of signal transduction pathways are a heterogenous, ill-defined group 
of defects that are usually associated with normal platelet count and morphology and 
includes receptor, G protein and effector defects. Historically, they were classified in 
the group of primary secretion defects (Rao and Gabbeta, 2000).  
The identification of the causative molecular defect in this group of disorders is 
challenging. A long list of patients with disorders of platelets due to abnormalities in 
signalling pathways have been reported. These patients showed an inhibition to one or 
usually more than one platelet agonist due to defects in aggregation, secretion and/or 
cytoskeletal responses. Beside the clinical manifestations of primary haemostatic 
defects (mild bleeding), most of these patients are likely to present with additional 
manifestations due to the contribution of the proteins of these signalling pathways in 
other cells in the body. Among those already described in this group are patients with 
impaired Ca+2 mobilization, defective inositol-1,4,5-trisphosphate production, reduced 
phosphorylation of pleckstrin by protein kinase C, a deficiency in phospholipase C-γ2 
isoform and a specific decrease in Gαq (Rao, 2003).  
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1.5 Testing for platelet disorders 
Multiple aetiologies exist for platelet-based bleeding disorders. Thorough evaluation of 
the patient’s medical history, concentrating on personal and familial bleeding disorders 
and current medications should be the initial step in determining whether a bleeding 
disorder is present. The laboratory evaluation of these disorders is challenging and can 
range from simple to complex. Moreover, since the last guidelines for the British 
Committee for Standards in Haematology (BCSH) on platelet function testing were 
written in the late 1980s (BCSH, 1988), many new tests have become available. Recent 
advances in genetic testing of platelet defects could also be used to rapidly diagnose 
defects and receptor polymorphisms in both health and disease, but this is seldom done.  
 
Platelet function tests are primarily utilized to aid in the diagnosis and management of 
patients presenting with bleeding problems rather than thrombosis. However, 
nowadays there is also renewed interest in monitoring the efficacy of anti-platelet 
therapy and measuring platelet hyper-function (Harrison, 2005).  
 
The bleeding time, the first physiological test of platelet function, measures the ability 
of platelets to arrest bleeding from standard sized cuts that are made within the skin of 
the forearm and, therefore, is a measure of both platelet number and function. In 
addition, this test also measures the integrity of the connective tissue. While the 
methodology for performing bleeding times has improved over the years, with the 
availability of devices to standardize the size and depth of the incisions, the bleeding 
time remains a test with considerable lack of precision and questionable correlation 
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with clinically significant patient conditions and has fallen from favor in recent years 
(Bolton-Maggs et al., 2006).   
 
The PFA-100 (Platelet Function Analyzer) (Mammen et al., 1998) has been introduced 
to the market to help monitor antithrombotic drug dosages or thrombotic risk. Recently, 
it has been widely utilized to diagnose platelet disorders as it simulates high shear 
platelet adhesion to foreign surfaces (e.g. collagen), mimicking many of the important 
physiological processes of platelet adhesion, activation and aggregation that occur at 
higher shear rates in vivo. It provides a potential replacement of the bleeding time as a 
screening test, and is abnormal in several other conditions most notably von 
Willebrand disease, which is the most common cause of bleeding. In addition, this 
procedure is sensitive to platelet count and hematocrit and full clinical use has yet to be 
established. So is there a single bed-side test that is definitive for a platelet-bleeding 
defect and indeed is such a test a reality? 
 
Almost certainly, there will never be a universal test on which to make a definite 
diagnosis in the case of a bleeding defect due to platelet dysfunction. Indeed, in this 
light, it is possible that the platelet aggregation test which was introduced in the early 
1960s, will remain as the most commonly used platelet function test used in academic 
centers and large hospitals. Aggregometers monitor the changes in light transmission 
that occur in a suspension of platelets that are stimulated with different concentrations 
of agonists (e.g. ADP, collagen, adrenaline, ristocetin etc). In addition, the 
lumiaggregometer has the ability to simultaneously measure ATP secretion from 
dense granules using luciferin-luciferase reagent. The pattern of responses obtained 
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enables the experienced operator to diagnose whether there are defects in platelet 
receptors, platelet secretion and downstream signaling or metabolic pathways, although 
it is inevitable that further tests will be needed to determine the cause of the disorder. 
Although this test is labor intensive and relatively slow and marked thrombocytopenia 
can make the aggregation responses difficult to interpret, it remain the most widely 
used and understood test to study platelets function defects.  
 
Platelet nucleotide tests are done to rule out storage pool defects unless the platelet 
aggregation test and simultaneous measure of the release of ATP from dense granules 
by using the lumiaggregometer has demonstrated no defect. 
 
Further investigations for the assessment of platelet function: 
These are specialist tests and perhaps require a specialist centre.    
 
Platelet flow cytometry is a sensitive and powerful tool for studying platelets with 
very small quantities of blood even in thrombocytopenia. However it requires a trained 
and experienced operator, and in general is an expensive item of equipment. The major 
diagnostic use of this technique is to determine the copy density of platelet membrane 
glycoproteins and receptors confirming the absence of various glycoproteins or 
receptors in diseases such as Glanzmann Thrombasthenia. Platelet function testing can 
also be performed and the ability of platelets to degranulate, express activation markers 
(e.g. P-selectin for α-granules and CD63 for dense granules) and negatively charged 
phospholipid in response to agonists can all be studied. In addition, dense granule 
contents measurement using mepacrine uptake and release, microparticle formation 
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and the recent VASP (Vasodilator Stimulated Phosphoprotein) test for monitoring 
aspirin and P2Y12  drugs  have all  been applied to platelet function testing with the 
help of the flow cytometry (Schmitz et al., 1998, Michelson et al., 2007).  
 
Electron microscopy is another helpful tool used in diagnosing platelet defects such 
as the lack of platelet dense granules in Hermansky Pudlak patients but is only 
available in few specialized centres. 
 
More specialized tests for platelet enzymes and signal transduction pathways: 
Once a defect in a platelet receptor or signaling pathway is suspected then other tests 
can be done in order to reach a definitive diagnosis, however these tests are not 
routinely undertaken but may be considered within a research context. 
 
An update on the current clinically available platelet function tests with the advantages 
and disadvantages of each test has been published recently (Harrison, 2009). 
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1.6 Aims of the thesis 
The overall aim of this thesis is to identify patients with mild bleeding disorders of 
platelet aetiology and to determine the underlying molecular cause.  This will be 
achieved as follows: 
• Generation of standard aggregation and dense granule secretion curves to major 
platelet agonists and evaluation of the effect of inhibition of the two feedback 
agonists, ADP and TxA2, using a Born-lumiaggregometer. 
• Testing patients with suspected platelet receptor defects from the Haemophilia 
Centre in Birmingham and in other Hospitals, notably Bristol and Sheffield, 
particularly those that appear to have a defect in the P2Y12 ADP receptor given the 
link to mild bleeding, and in comparison to standard curves. 
• Testing of patients with type I VWD from the European cohort for possible defects 
in the P2Y12 ADP receptor, in view of the increasing evidence that this is a 
polygenic disorder, especially in patients with only a partial reduction in VWF. The 
application will investigate the hypothesis that the similarity in the pattern of 
bleeding of patients with type I VWD and mild-platelet based disorders, and the 
incomplete penetrance of bleeding in these two disorders, is because these patients 
have defects in both pathways.  The genetic sequencing for these studies has been 
performed in Dr Martina Daly’s laboratory in the University of  Sheffield, and my 
role has been linked to the functional characterization of the patients. 
• More focused tests to identify the nature of the defects discovered for the above 
patients e.g. cAMP and Ca2+ and then genetic analysis. 
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2.1 Materials 
 
Trisodium citrate, ADP, adrenaline, U46619, arachidonic acid, indomethacin, PGI2 and 
MRS2179 were purchased from Sigma-Aldrich (Poole, UK). Horm collagen was 
purchased from Nycomed Austria (Linz, Austria). The PAR1 peptide SFLLRN was 
purchased from Alta Bioscience Laboratory (University of Birmingham, UK). The 
PAR4 peptide AYPGKF and CRP was purchased from Dr Richard Farndale 
(Cambridge University, UK). AR-C67085 was a gift from Astrazeneca (Loughborough, 
UK). Luciferin/luciferase reagent (Chrono-lume) and ATP standard were purchased 
from Chrono-log Corporation (Havertown, PA, USA). Platelet aggregation and 
secretion was performed on a Dual Channel Lumi-Aggregometer (model 460VS, 
Chronolog). cAMP Biotrak enzyme immunoassay kit and ELISA TxB2 assay kit were 
purchased from GE Healthcare UK Ltd. Anti COX-1 mAb and anti TXAS mAb raised 
in mouse were purchased from Cayman chemical (IDS.LTD, Boldon, UK) Anti GPVI 
mAb raised in mouse was a gift from Dr. M Moroi-Japan (Moroi et al., 2003). Anti-
actin mAb AC-40 raised in mouse was from Sigma Aldrich. The rest of the materials 
used in this thesis, unless stated, were purchased from Sigma Aldrich (Poole, UK).  
ADP (10 mM), adrenaline (100 mM), arachidonic acid (15mM) and PAR1-peptide (10 
mM), PAR4-peptide (500 mM), MRS2179 (10mM) and AR-C67085 (10mM) were 
dissolved in phosphate-buffered saline (PBS) and stored as frozen aliquots at the 
concentrations shown and diluted in PBS on the day of the experiment. CRP (1.4 
mg/ml stock) was cross linked accorded to the recommended protocol as described in 
Appendix1 and stored at 4○C then diluted in 0.01M acetic acid in PBS containing 0.1% 
fatty acid-free bovine serum albumin on the day of the experiment. Collagen was 
stored as a concentrated stock at 1mg/ml as supplied by the manufacturer at 4○C. 
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Indomethacin (10mM) was stored and diluted in dimethyl sulphoxide (DMSO). 
U46619 (1mM) was stored in DMSO and diluted in PBS on the day of the experiments. 
Agents were added in dilutions of 1: 100, with the exception of  indomethacin which 
was added at a dilution of 1: 1000 to keep the DMSO concentration to 0.1%. 
 
2.2 Platelet preparation 
 
2.2.1 Preparation of platelet rich plasma 
Blood samples were taken from healthy donors who gave informed consent and 
answered negatively to routine deferral questions such as ingestion of aspirin and other 
agents that may influence platelet function. Blood was also taken from patients with a 
suspected or known platelet defect. Whole blood was anticoagulated with 4% 
trisodium citrate (trisodium citrate/whole blood ratio, 1:9), by collecting 50 ml blood 
using a 21G needle into a plastic polypropylene syringe containing anticoagulant. The 
blood was transferred to 5ml polypropylene tubes, 75 x 12mm, for centrifugation. 
Platelet rich plasma (PRP) was prepared by centrifugation of anticoagulated blood at 
170 g for 10 minutes at room temperature (20 – 22 ○C). The PRP (upper layer) was 
gently pipetted into a 50ml polypropylene tube using a plastic pipette. The blood was 
recentrifuged at 190 g for 10 minutes at room temperature and further PRP collected in 
the same way and pooled. The use of two centrifugation steps increases the yield of 
PRP. The platelet number was measured using a Coulter Z2 analyser (Beckman Coulter 
(UK) Ltd), but was not adjusted prior to experimentation.  
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2.2.2 Preparation of platelet poor plasma 
Platelet-poor plasma (PPP) was prepared by centrifuging the blood remained from the 
preparation of PRP (discussed above) at 1000 g for 10 minutes at room temperature. 
 
2.2.3 Preparation of washed platelets 
Washed platelets were obtained from PRP that was collected after centrifugation of the 
blood for 20 minutes at 200g as described by Watson et al (Watson et al., 1995). PRP, 
after the addition of 1 µg/ml prostacyclin (PGI2), was centrifuged at 1000 g for 10 
minutes. The platelet pellet was suspended in 3 ml ACD with 25 ml (pH 7.3) HEPES-
buffered Tyrode’s buffer (134 mM NaCl, 2.9 mM KCl, 1 mM MgCl2, 20 mM HEPES, 
12mM NaHCO3, 5 mM glucose). Following addition of 1 µg/ml PGI2, a second 
centrifugation was performed at 1000 g for 10 minutes. Platelets were finally 
resuspended with HEPES-buffered Tyrode’s to a chosen concentration.  
 
2.2.4 Platelet fixation for [3H]2MeSADP binding 
Fixed washed platelets were prepared based on the method described by Mundell et al 
(Mundell et al., 2006). PGI2 (1µg/ml) was added to PRP, which was then centrifuged at 
1000g for 10 minutes before resuspension at 4 x 108  platelets/ml in modified Tyrode’s-
HEPES buffer (145 mM NaCl, 2.9 mM KCl, 10 mM HEPES, 1 mM MgCl2, and 5 mM 
glucose, pH 7.3). Apyrase (0.02 U/ml) and formaldehyde (4 %) were added to the 
platelet suspension, which left to rotate for 25 minutes at room temperature. The 
suspension was then centrifuged at 1000g for 10 minutes, and the pellet resuspended in 
binding buffer (20 mM HEPES and 1mM MgCl2, pH 7.3) to a density of 4x108 
platelets/ml. 
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2.3 Platelet functional assays 
 
2.3.1 Platelet aggregation 
Platelet aggregation was measured by a turbidimetric method which moniters light 
transmission (Born, 1962, O'Brien, 1962), using a Dual Channel Lumi-Aggregometer 
(460VS, Chronolog). This aggregometer incorporates a luminometer that permits 
simultaneous monitoring of platelet aggregation and release of ATP in siliconized glass 
cuvettes (Labmedics, Manchester, UK). The PRP and PPP or washed platelets and 
buffer samples, were used to set the scale prior to the onset of the aggregation 
recording. The difference between the light transmission of the PRP and PPP samples 
is taken as 100%, with the initial starting trace representing 0%. Samples (396 µl) were 
prewarmed at 37 ○C for 120 seconds and stirred at 1200 rpm for 60 seconds before 
agonist addition. Agonist dilutions are typically 1:100 i.e. 4 µl with the exception of 
these dissolved in DMSO. Antagonists and inhibitors were given 120 seconds before 
experimentation. A summary of platelet agonists, antagonists and inhibitors is given in 
Table 2.1. Platelet aggregation was determined by measurement of the change in 
optical density (i.e. light transmission) after agonist addition. Each sample was 
compared relative to the PPP control. Platelet aggregation was monitored for more than 
5 minutes. The maximum extent of aggregation was calculated and expressed as a 
percentage of full-scale deflection as measured by PPP.    
  73
 
Chapter 2 – Materials and methods 
  74
 
Chapter 2 – Materials and methods 
2.3.2 Platelet ATP secretion 
This is a technique based on firefly bioluminescence. In this assay light is produced in 
proportion to the concentration of ATP released from platelets. 400 µl PRP was 
activated by one of the agonists listed in Table 1.2, in the presence of 40 µl of Chrono-
lume luciferin/luciferase reagent (Labmedics, Manchester, UK), which was diluted 
according to the manusfacturer’s instructions and given 120 s before experimentation. 
The ATP secreted was measured with a Dual Channel Lumi-Aggregometer. Changes 
in luminescence were quantified through calibration with 4 nmol ATP standard for 
each sample. Data was normalized to the level of secretion per 1x 108 platelets. 
 
2.4 Adenylyl cyclase activity (cAMP assay) 
Adenylyl cyclase activity in platelets was assessed by measurement of cAMP. In order 
to quantify cAMP in platelet samples, Amersham cAMP Biotrak enzyme immunoassay 
kit was used, which is based on competition between unlabelled cAMP and a fixed 
quantity of peroxidase-labelled cAMP, for a limited number of binding sites on a 
cAMP specific antibody. 
Blood samples from both controls and patients with a suspected ADP 
receptor/signaling pathway defect were collected. 160 µl of washed platelets, at a 
concentration of 6x107/ ml in Tyrode’s buffer were incubated with 1 µM PGE1 for 15 
minutes, after which, platelets were stimulated with either ADP or adrenaline for 
another 15 minutes followed by the addition of the lysis reagent (2.5% solution of 
Dodecyltrimethylammonium Bromide in assay buffer) through successive pipetting to 
facilitate cell lysis. After incubation for 10 minutes at room temperature, the samples 
were stored at -20○ C. Basal and stimulated samples were thawed and cAMP was 
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measured using protocols stated in the manufacturer’s guidelines. The 96-well ELISA 
plate was analysed on a VERSAmax tunable microplate reader (Molecular devices, 
UK.) Data analysis was subsequently conducted using Graph Pad prism 4 software, 
using a standard curve constructed from a serial dilution of working standard samples 
to calculate cAMP production. 
 
2.5 Measurement of platelet nucleotides 
In this procedure ATP and ADP levels in platelet are measured using a luminometric 
assay (Jarvis et al., 1996). The light produced by the firely luciferin/luciferase reagent in 
the microplate luminometer (Berthold technologies-centro LB960) is proportional to the 
amount of ATP available in the platelet sample. The ADP level was detected following 
convertion of ADP to ATP via the phosphoenol pyruvate/pyruvate kinase reaction. PRP 
for this assay was prepared by centrifugation of citrated blood at 170g for 10 minutes, 
with no second centrifugation step. This PRP has to be processed within 3 hours of 
collection. 25μl EDTA (0.1M) , 10% Triton X-100 (vortex, mix well) and 250μl ethanol 
were added to 250μl PRP and mixed for 30 minutes before storage at -20°C until required.  
An ATP standard curve was prepared from serial 1/10 dilutions of an ATP standard (10 
µM stock) in assay buffer and this was used to calculate the ratio of ADP:ATP and 
absolute amount of ATP and total ADP+ATP. The final results are expressed as nmoles 
nucleotide/108 platelets. The calculation is done for both total and ATP only. The ADP 
content is then calculated by subtracting the ATP reading from the total.  
 
 
2.6 Thromboxane B2 assay 
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In order to quantify thromboxane B2 (TxB2), the TxA2 stable metabolite, we used an 
ELISA TxB2 assay (GE Healthcare UK Ltd.) which is based on the competition 
between unlabelled TxB2 and a fixed quantity of peroxidase-labelled TxB2 for a TxB2 
antibody. Washed platelets samples (4 x 108 / ml) from controls and patients with a 
suspected platelet-based TxA2 pathway defect were stimulated for 5 minutes with 1 
µM arachidonic acid. The reaction was then stopped by addition of 50μM 
indomethacin and 2 mM EDTA. Samples were centrifuged at 14000g for 2 minutes 
and the supernatant stored at -20○ C. All samples (basal and stimulated) were thawed 
and diluted 1:1000 using Tyrode’s buffer prior to commencing the assay. The assay 
was conducted using protocols stated in the manufacturer’s guidelines. The 96-well 
ELISA plate was analysed on a VERSAmax tunable microplate reader (Molecular 
devices, UK.) Data analysis was subsequently conducted using Graph Pad prism 4 
program, using a standard curve constructed from a serial dilution of working standard 
samples to calculate TxB2 production in patient samples. 
 
2.7 Protein expression analysis 
 
2.7.1 Western- blotting 
Washed platelet samples were prepared (as described in Section 2.2.3). Proteins were 
extracted from platelet preparations by addition of an equal volume of 2x Laemmli 
sample buffer (2x Laemmli buffer is: 4% SDS, 10% 2-mercaptoethanol, 20% Glycerol, 
10% stacking gel buffer; where stacking gel buffer is: 0.5M tris HCl at PH 6.8). 
Samples were separated by sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE) using 10% gradient gels. The gels containing the 
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separated proteins were transfered into polyvinylidene difluoride (PVDF) membranes 
using a semi-dry method. Blocking of the membranes were done immediately with 5 % 
(w/v) non-fat dry milk in TBS-T ( 0.5 M Tris, 1.5 M NaCl, 0.1 % (v/v) Tween 20, PH 
7.4) for an hour then subsequent incubation with the primary antibody at the 
appropriate dilution in 3 % (w/v) bovine serum albumin with 0.1% sodium azide in 
TBS-T for 90 minutes. Washings with high salt TBS-T (5 M NaCl) were performed 3 
times with a 15 minutes interval between each wash. Blots were incubated with 
secondary antibody in 5% (w/v) non-fat dry milk in TBS-T for 90 minutes then 
washing 3 times as before and finally developing using the enhanced chemi-
luminescence (ECL) detection system (Pierce Bioscience). This is based on incubation 
of the western blot with a substrate that will luminesce when exposed to the reporter on 
the secondary antibody and the light is then detected by photographic film. 
Quantitation of band volumes was done using the Syngene GeneGnome HR bio 
imaging system (Synoptics, Cambridge, UK) using the GeneSnap software provided 
along side the system. To re-probe a membrane, blots were incubated in stripping 
buffer (2% SDS in TBS-T) plus 2% 2-mercaptoethanol at 80 ○C for 20 minutes, then in 
stripping buffer for a further 20 minutes at 80 ○C. Blots were washed thouroughly in 
TBS-T and re-blocked with 5 % (w/v) non-fat dry milk in TBS-T before re-probing.  
 
2.7.2 Measurement of GPVI by flow cytometry 
PRP, after being diluted to 1 x 107 /ml in PBS with the presence of 1mM EGTA, was 
stimulated for 5 minutes with platelet agonists or its vehicle at 37 ○C. Platelets (45 µl) 
were incubated with 5 µl of GPVI antibody (in PBS), bringing it to a final antibody 
concentration of 10µg/ml, for 20 minutes. The samples were then centrifuged for 5 
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minutes at 1000g, and a secondary FITC-conjugated anti-mouse antibody added to the 
pellet, mixed and incubated for 20 minutes. The sample was then diluted to 500 µl 
before subsequent flow cytometry in the FACS Calibur flowcytometer (Becton 
Dickinson UK Ltd). Cell Quest programme was used for obtaining and analyzing the 
data.  
 
2.8 Dense granules evaluation by Transmission Electron Microscopy 
A modification of the whole mount procedure for sample preparation explained in 
“Methods in molecular biology: Platelet and Megakaryocytes” (White, 2004) has been 
done as follows: 
1- Smal1 drops of PRP (prepared as discussed in Section 2.2.1) were placed on six 
Formvar coated grids (supplied by the electron microscopy centre-University of 
Birmingham), placed on a sheet of parafilm, rinsed in PBS after 5-7 minutes then fixed 
with 3-4 drops of 2.5% glutaraldehyde in PBS for 5 minutes. A second rinse for three 
times in dH2O was done and then the grids were dried from the edge with pieces of 
filter paper.   
2- The grids were inserted into the Transmission electron microscope (TEM) at the 
electron microscopy centre-University of Birmingham (Jeol 1200EX TEM -JEOL 
(U.K.) LTD, Herts, England) and the dense granules were counted in at least 50 
platelets spread on the grids. 
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2.9 Data analysis 
 
2.9.1 Aggregation  
The degree of aggregation at 90 s or 180 s was measured and reported as a percentage 
of the difference in light transmission between the PRP and PPP samples. It should be 
noted that in cases of transient aggregation, the response at 90 s can be larger than that 
at 180 s. Results are shown as mean ± S.D. from 3–20 experiments. Concentration-
response curves were fitted to a three variable logistic equation, with EC50, Hill slope 
and maximal response, as variables using Graphpad Prism software. Statistical 
indications were made using Student’s t-test, with P < 0.05 taken as the level of 
significance. 
 
2.9.2 ATP secretion 
ATP secretion was calculated by addition of a known concentration of ATP (4 nmol) 
and normalize the platelet count to 1x 108/ platelets. 
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3.1 Aim 
 
 
The aim of the work in this chapter is to establish the reproducibility of aggregation 
and dense granule secretion over a variety of parameters such as time, platelet count 
and between donors, and to establish reference curves to low, intermediate and high 
concentrations of platelet agonists in the absence and presence of ADP receptor 
antagonists and cyclooxygenase inhibition. The latter inhibitors were used because 
they block the action of the two major feedback agonists, ADP and TxA2, which 
reinforce platelet activation to all agonists.  Importantly, several of the agonists chosen 
for investigation are not routinely used in clinical testing, but they have been included 
to help in the diagnosis of what are anticipated to be the more common causes of mild 
platelet-based disorders. These include the thromboxane analogue, U46619, PAR1 and 
PAR4 thrombin receptor-specific peptides, and the GPVI collagen receptor agonist, 
collagen-related peptide (CRP). The results provide a valuable resource of data to aid 
patient testing and suggest that, if used within certain boundaries, the simultaneous 
investigation of platelet aggregation and ATP secretion is a powerful way to aid 
diagnosis of patients with platelet-based bleeding disorders. 
 
3.2 Introduction 
 
Platelet function testing is routinely used in the clinic to diagnose patients with 
suspected platelet-based bleeding disorders. One of the most widely used tests for 
assessing platelet reactivity is platelet aggregation in platelet-rich plasma (PRP). 
However, there is no accepted way to perform or interpret these studies (Zhou and 
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Schmaier, 2005), with practices varying between laboratories as documented in a 
review of 46 North American Clinical Laboratories (Moffat et al., 2005). Variables 
include factors such as sample collection, platelet preparation, platelet count, agonist 
selection and agonist concentrations. Furthermore, the full value of aggregometry is 
seldom achieved because of the use of a limited number of agonists and concentrations. 
Indeed, aggregation methodology has remained largely unchanged since the late 1980s 
despite important advances in our understanding of platelet activation. For example, 
the guidelines in the UK for investigation of patients with suspected platelet-based 
bleeding disorders, including information on platelet aggregation, were drawn up by 
the British Society for Haematology Task Force in 1988 (BCSH, 1988) before the 
majority of the platelet surface receptor were first cloned. A more recent report on 
behalf of the Rare Haemostatic Disorders Working Party of the UK Haemophilia 
Centre Doctors Organisation (UKHCDO) summarizes heritable platelet disorders and 
gives guidelines on their analysis and clinical management (Bolton-Maggs et al., 2006). 
This report emphasizes the importance of aggregation testing in clinical diagnosis but 
does not give experimental details on how to perform these studies. Further, 
development of expertise in platelet function testing is hampered by the small number 
of clinical patients who require testing and by the even smaller number of patients with 
defined, platelet-based disorders. The interpretation of aggregation concentration 
response curves in patients is highly specialized because of the complexity of 
interacting mechanisms that coordinate the aggregation response. A defect in response 
to more than one platelet agonist could be due to a generalized defect in platelet 
activation, to impairment in release of the major feedback mediators, ADP and TxA2, 
or to a defect in the P2Y12 receptor for ADP or in the thromboxane receptor. A defect 
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in the P2Y12 ADP receptor, for example, would result in abnormal responses to low 
concentrations of nearly all platelet agonists, including arachidonic acid, which is 
frequently used to investigate defects in the cyclooxygenase pathway. On the other 
hand, a defect in the P2Y1 ADP receptor would have a more selective effect because it 
generates a relatively weak signal and its activation is masked by receptors which 
signal through the same pathway, such as the thromboxane receptor and the two 
thrombin receptors, PAR1 and PAR4 (Woulfe, 2005). The interpretation of 
aggregation traces is also influenced by the natural variation in responses that exist 
within the population, thereby making it essential for each laboratory to have standard 
reference curves for comparison to patients’ responses. For example, a study on 
aggregation responses in 359 healthy individuals identified a subset of donors with 
hyper-responsive platelets which was maintained over independent experiments (Yee 
et al., 2005). Several laboratories have published their own methods for monitoring 
platelet aggregation (Zhou and Schmaier, 2005, Hayward et al., 2008), but none has 
used as many platelet agonists as has been used in our investigation or evaluated 
responses in the presence of inhibitors of the two major feedback inhibitors, ADP and 
TxA2. Further, few laboratories have extended their analysis to the simultaneous 
monitoring of ATP secretion from dense granules, despite the availability of lumi-
aggregometers for more than 25 years and recognition of the value of monitoring ATP 
secretion in diagnosis (Hayward et al., 2006b). 
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3.3 Results 
 
The results in this chapter are divided into two sections. The first describes the 
characterisation of the conditions used for monitoring aggregation and secretion, and 
the concentration response curves to the platelets agonists chosen for investigation.  
The second describes the effect of inhibition of the two platelet ADP receptors, P2Y1 
and P2Y12, and cyclooxygenase on aggregation and secretion to low, intermediate and 
high concentrations of eight platelet agonists.  
 
Section A: Reference curves for platelet aggregation and secretion 
 
3.3.1 Characterization of aggregation  
An initial series of experiments was designed to establish the extent of variation in 
platelet aggregation to a range of receptor agonists within a population of healthy 
volunteers who had denied having recently taken medication that is known to alter 
platelet function. These initial studies were performed with a limited number of platelet 
agonists: ADP, adrenaline, collagen, PAR1 peptide, arachidonic acid and U46619. 
Shape change, percentage of maximal aggregation, the rate of aggregation (where the 
steepest part of a slope versus time was taken) and the pattern of aggregation response 
were monitored in each experiment.   
Sodium citrate was chosen as the anticoagulant as this is routinely used in 
clinical laboratories for platelet testing at a concentration of either 3.2 or 3.8%.  As 
shown in the aggregation traces to ADP in Figure 3.1 and the dose response curves to 
representative agonists in Figure 3.2, we observed no difference in response in the 
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presence of either 3.2 or 4.0% sodium citrate to any of the agonists.  Please note in 
these initial experiments, aggregation was monitored at 90 sec in order to focus on the 
initial component of the response.   For this reason, the maximal level of aggregation to 
adrenaline is less than that to other agonists, as the second wave of the response peaks 
after this time (see later).  Based on these results, a decision was made to use 4% 
sodium citrate in subsequent studies, as we have routinely used this in our previous 
work over the course of many years. This concentration was then used in studies 
designed to investigate the dependency of aggregation on sex, a limited age range 
(reflecting those found in our pool of donors), platelet count and time after donation, 
along with the reproducibility of aggregation within individual donors over time.   
 86
 
Chapter 3 - Reference curves for aggregation and secretion 
 
 87
 
Chapter 3 - Reference curves for aggregation and secretion 
 88
 
Chapter 3 - Reference curves for aggregation and secretion 
I initially investigated the extent to which aggregation deteriorates with time following 
both donation and platelet preparation. These are two crucial questions as the 
examination of the aggregation and secretion to low, intermediate and high 
concentrations of a range of platelet agonists can take several hours. Further, to 
increase access to patients, it was necessary to establish whether we could transport 
anti-coagulated blood and subsequently prepare platelets in Birmingham without loss 
of response. In this regard, I have demonstrated that storage of blood in the presence of 
sodium citrate (4%) at room temperature for up to 4 hours prior to platelet preparation 
had a minimal effect on responses to all agonists, although a small reduction in 
response was observed when blood was left for up to six hours (Figure 3.3). 
Importantly, when samples were kept in PRP at room temperature for up to 6 hours, 
platelet responses to all agonists, including ADP, were maintained (not shown).  
Subsequent studies were therefore usually performed on PRP samples that were 
prepared within 60 minutes of blood donation and analysed within 6 hours.  In later 
studies using patient samples, this was not always possible due to the need to transport 
the blood to Birmingham and so a control was always taken alongside for comparison.  
In all cases, the time of transport to platelet preparation never exceeded four hours.   
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I then evaluated concentration response curves for platelet aggregation to ADP, 
adrenaline, collagen, PAR1 peptide, arachidonic acid and U46619 in 10 male and 10 
female donors aged between 21 and 46 years, reflecting the range of ages of available 
donors. Similar results were obtained for percentage or rate of aggregation in the two 
populations (Figures 3.4 and 3.5) demonstrating no significant sex variation in 
response. Further, because the concentration response curves for the degree and rate of 
aggregation were similar, a decision was made to only analyse the degree of 
aggregation in subsequent studies.  This work was also extended to investigate the 
effect of age on the concentration response curves to the above agonists, taking into 
account the range of ages that are found in our cohort of donors. There was no 
significant difference in response between donors of below 25 and above 35 yrs of age 
(Figure 3.6).  
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A potentially important variable in these studies is platelet count, as many laboratories 
routinely normalise the count between controls and patients through dilution using 
platelet poor plasma (PPP).  Further, it was anticipated that a significant number of 
patients with suspected mild platelet disorders would be thrombocytopenic.  The 
practice of diluting platelet rich plasma (PRP) with PPP has however been shown to 
reduce platelet activation in several independent studies, thereby bringing this into 
question (Lecchi, 2005, Cattaneo et al., 2007, Mani et al., 2005).  For this reason, the 
platelet concentration was not adjusted and aggregation curves were compared in 
relation to platelet count.  To justify this I divided controls into those with a platelet 
count in PRP of between 2–3 x 108/ml or 5–6 x 108/ml and compared the concentration 
response curves to ADP, PAR1 peptide and collagen. As shown in Figure 3.7, there 
was no significant difference between the two sets of curves for low, intermediate and 
high concentrations of the three agonists.  In further studies (not shown), performed on 
washed platelets, I observed a shift to the right in the dose response curve to collagen 
when the platelet count was reduced to less than 1.5 x 108/ml, thereby restricting 
aggregation studies (without alteration of platelet count) to between 1.5–6 x 108/ml in 
PRP.  
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Despite the high level of reproducibility, small differences between donors in the 
concentration response curves for specific platelet agonists were observed, with the 
most marked difference being seen with ADP, although all of the response curves fell 
within a 2–3 fold concentration range.  The explanation as to why the greatest variation 
in response is seen with ADP may reflect that it mediates activation through the 
synergistic interaction of two receptors, one of which, the P2Y1, is expressed at very 
low level (approximately 150 copies per platelet). Importantly, differences in the 
agonist response curves were maintained between donors, as illustrated by the response 
to ADP in two example donors in Figure 3.8, performed within 10–12 weeks of each 
other. In this example, donor 1 has a greater sensitivity to ADP than donor 2. This is 
particularly apparent at 1 or 3 µM ADP which generate reversible or biphasic 
irreversible aggregation respectively, in donor 1, compared with shape change or 
reversible aggregation respectively, in donor 2. Further, at the higher concentration of 
10 µM ADP, the response in donor 2 can clearly be seen to be biphasic whereas only a 
single, rapid aggregation response is observed in donor 1. Indeed, small differences in 
response to multiple  agonists between individuals who have donated blood on 
multiple occasions have been maintained over a course of several years in our 
laboratory (not shown).  This variation in response between donors emphasizes the 
importance of generating reference curves within a population of healthy volunteers.  
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3.3.2 Initial characterization of secretion responses 
Following the above studies, measurement of ATP release as a monitor of dense 
granule secretion alongside aggregation was undertaken in healthy volunteers using 
luciferin-luciferase. ATP is secreted from dense granules in a constant ratio to ADP of 
2:3 (BCSH, 1988, Akkerman et al., 1983). Data was normalized to the level of 
secretion of ATP per 108 platelets. Normalization of the data in this way was found to 
be essential because of the variation in platelet count, as illustrated for platelets 
stimulated by (100 µM) PAR1 (Figure 3.9).   
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3.3.3 Reference concentration response curves  
The previously described studies were performed with ADP, adrenaline, collagen, 
PAR1 peptide, arachidonic acid and U46619. To this list, I added the synthetic 
collagen CRP, PAR4 petpide and ristocetin.  CRP was included because it has been 
shown in mouse platelets to more readily detect a reduction in the level of the collagen 
receptor GPVI relative to collagen, which also binds to integrin α2β1.  The PAR4 
peptide selectively activates the PAR4 receptor, which is generally considered to be the 
more minor of the two thrombin receptors.  Ristocetin mediates platelet agglutination 
through via the GPIb-IX-V complex. The concentration response curves for 
aggregation and secretion, measured at 90 and 180 sec, respectively, were determined 
to the above agonists in 8–20 controls.  There was no adjustment for platelet count (2–
6x108/ml), age (20–55 years) and sex, and all experimentation was performed within 6 
hours of platelet preparation.  The reference curves are shown in Figure 3.10 and, in 
the case of ristocetin, Figure 3.11.  It was not possible to record the ATP secretion to 
ristocetin due to interference of ristocetin with the luciferin luciferase reagent.  There 
was a high level of reproducibility in the response curves in all cases, with nearly all 
standard deviation values falling within 20% of the mean.  The pattern of aggregation 
response to each of the agonists used will be discussed in detail in Section B.  
 101
 
Chapter 3 - Reference curves for aggregation and secretion 
 102
 
Chapter 3 - Reference curves for aggregation and secretion 
 103
 
Chapter 3 - Reference curves for aggregation and secretion 
The location of the concentration response curves for ATP secretion corresponded to 
those for aggregation for all agonists with the exception of ADP, where the 
concentration response curve for ATP secretion was located approximately three-fold 
to the right of that for aggregation. This indicates that secretion of ADP reinforces 
aggregation to all agonists with the exception of ADP itself.  The former statement is 
confirmed by the studies in Section B which investigate the effect of inhibition of P2Y1 
and P2Y12 receptors on aggregation.  PAR1 peptide stimulated the largest level of 
secretion of ATP, although maximal responses to all agonists fell within 50% of this 
response (Figure 3.10). Thus, these results indicate a high level of reproducibility in 
ATP secretion, thereby supporting previous studies that have indicated ATP secretion 
as a valuable marker of platelet activation.   
 
3.3.4 Aggregation and secretion data in 60 controls 
The studies described above were performed at the outset of the project, and before 
studies on patients had begun.  Over the following period of more than 3 years, platelet 
aggregation and secretion responses to the above agonists were continually monitored 
in controls performed alongside patients. This has now increased the number of 
controls that have been analysed to over 60 and has enabled us to further assess the 
reproducibility in response between individuals. This data is summarised in Figure 
3.12 with the response of each individual represented by a single dot for each 
concentration of agonist.  Since several individuals have been analysed on more than 
one occasion, I have only included the results from the first experiment on that 
individual. I have chosen to illustrate the data as the response of each individual as 
outliers can be masked through meaning of data and not each concentration of agonist 
 104
 
Chapter 3 - Reference curves for aggregation and secretion 
was used on each control, as the study was guided by the results in the patient.  Thus, 
for example, if the response to a submaximal concentration of an agonist such as PAR1 
peptide was normal, I may not have gone on to monitor the response to a lower / higher 
concentration, taking into consideration also volume of blood, time and the response to 
other agonists.  Data has been presented for three agonists, ADP, PAR1 and collagen, 
as these signal through a distinct set of receptors.  Two higher concentrations of ADP 
(30 and 100 µM) have been included. ATP secretion from dense granules was also 
measured in this group of controls in response to the highest concentration of each 
agonist and is shown in Figure 3.13.   
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The striking observation from this data is the level of reproducibility which confirms 
the conclusion from the smaller studies described above.  The most variable response 
was seen with ADP (3 μM), which ranged from < 10% to over 50% aggregation.  
Importantly, however, at a three fold lower concentration, the response to ADP was 
always less than 30%, while at a threefold higher concentration, it was equal to or 
greater than 30%. A small number of individuals did show a hyper response to the 
lowest concentration of PAR1 peptide that was used (10 μM), whereas in contrast, 4 
individuals showed a reduced response to 30 μM peptide. Overall though the level of 
reproducibility is impressive and we can say with confidence, for example, that a 
patient with a reduced aggregation to single concentrations of ADP (30 μM), PAR1 
(100 μM) and collagen (3 μg/ml) must have a platelet defect.  
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Section B 
 
3.3.5 Analysis of aggregation and dense granule secretion to platelet agonists in 
the presence of ADP receptor antagonists and cyclooxygenase inhibition 
ADP and TxA2 play a critical feedback role in mediating platelet activation. A defect 
in their release or in the function of their receptors has a widespread inhibitory effect 
on platelet activation. However, the bleeding phenotype of the defect differs according 
to whether secretion is disrupted or receptor function is impaired. To characterize this 
in full, we have investigated aggregation and dense granule secretion induced by low, 
intermediate and high concentrations of platelet agonists in the absence and presence 
of antagonists of the two ADP receptors, P2Y1 and P2Y12, namely MRS 2179 (100 
μM) and ARC-67085 (1μM), respectively, and the cyclooxygenase inhibitor, 
indomethacin (10 μM), which blocks the liberation of TxA2. All of the inhibitors were 
used at maximally-effective concentrations, as shown by the observation that a 5-10 
fold higher concentration of each inhibitor did not have an additional effect on platelet 
activation to ADP or arachidonic acid, even though both agonists caused a small 
response in the presence of the two receptor antagonists or cyclooxygenase, 
respectively (Figure 3.14). The residual response to ADP that is seen in the presence of 
either of the receptor antagonists can be explained by the presence of the other ADP 
receptor as discussed below.  The weak, residual response to arachidonic acid, which 
was manifest as shape change and very weak aggregation (< 10% of maximal 
aggregation) indicates a cyclooxygenase-independent actions, as also described by 
others (Frelinger et al., 2006).  
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The effect of the two ADP receptor antagonists or cyclooxygenase inhibition on 
aggregation and dense granule secretion to ADP, adrenaline, PAR1 and PAR4 peptides, 
collagen, CRP, U46619 and arachidonic acid was investigated in a minimum of three 
donors for each agonist (Figure 3.15 and 3.16). All responses were monitored at 180 
sec as secretion has peaked by this time and biphasic aggregation can be readily seen in 
the majority of controls. Each aggregation response curve was fitted to a three variable 
logistic equation using Graphpad Prism software to calculate the EC50 and 95% 
confidence levels as shown in Table 3.1. A similar analysis was not performed for ATP 
secretion because of uncertainty in the maximal response.  The effect of the inhibitors 
on the above agonists and the pattern of response to low, intermediate and high 
concentrations of each agonist are discussed below.  
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3.3.6 Aggregation and dense granule secretion in the presence of ADP receptor 
antagonists and cyclooxygenase inhibition 
Example traces showing aggregation and dense granule secretion in response to low, 
intermediate and high concentrations of platelets agonists, in the presence and absence 
of inhibitors, are shown in Figures 3.17 –3.25 and are discussed below. 
 
ADP 
ADP stimulates platelet aggregation through a synergy between P2Y1 and P2Y12 
receptors which are coupled to the Gq and G13 families, and the Gi family of 
heterotrimeric G proteins, respectively. The P2Y12 receptor is recognized to undergo 
marked synergy with receptors that signal through Gq and G13 to mediate powerful 
aggregation and secretion. In the representative trace, an intermediate concentration of 
ADP (3 µM) induces biphasic aggregation as shown by an initial rapid response 
followed by a delayed second phase (Figure 3.17).  This pattern of response is seen in 
most but not all donors as illustrated in Figure 3.8. The second phase is absent at a 
lower concentration of ADP (1 µM) and the two phases are less distinct at a higher 
concentration of ADP (10 µM). Sustained aggregation at intermediate and high 
concentrations of ADP (3 and 10 µM respectively) is dependent on release of 
thromboxane, as illustrated by deaggregation in the presence of indomethacin, 
although this is notably much slower at the higher concentration of ADP (Figure 3.17). 
Indomethacin also causes a complete inhibition of dense granule secretion to ADP 
(Figure 3.17).  The loss of the second wave of aggregation is most likely due to the 
absence of synergy between TxA2 and ADP rather than loss of secretion, as the latter is 
not thought to contribute to ADP-induced aggregation (see Section 3.3.3 and Figure 
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3.10), a result that was confirmed using platelets from two patients with Hermansky-
Pudlak syndrome-8 (HPS-8) (see Chapter 4-Figure 4.3).  HPS-8 is a recently identified 
form of the dense granule disorder that is caused by a mutation in BLOC1S3 and so 
they are unable to form platelet dense granules.   In contrast, blockade of the two P2Y 
ADP receptors causes a qualitatively distinct pattern of inhibition to that seen with 
indomethacin. The P2Y1 receptor antagonist, MRS2179, completely inhibits shape 
change (i.e. the initial transient increase in optical density) to all concentrations of 
ADP and also markedly reduces the extent of aggregation and dense granule secretion 
(3.17). Significantly, however, a low level of aggregation to ADP in the presence of 
MRS2179 is sustained and dense granule secretion is induced by a high concentration 
of ADP (Figure 3.17). On the other hand, the P2Y12 receptor antagonist, AR-C67085, 
has no effect on shape change but converts aggregation to a transient response that 
returns to the base-line within 2 minutes at all three concentratons of ADP that were 
investigated (Figure 3.17). In addition, dense granule secretion is abolished to all 
concentrations of ADP in the presence of AR-C67085 (Figure 3.17). The results 
demonstrate a critical role for the P2Y1 receptor in mediating shape change and in 
synergising with the P2Y12 ADP receptor to mediate aggregation and secretion. The 
inhibitory effect of AR-C67085 demonstrates the critical role of the P2Y12 ADP 
receptor in initiating and sustaining aggregation, as well as in mediating secretion. 
Thus, these results demonstrate that blockade of the two ADP receptors or 
cyclooxygenase has distinct effects on aggregation and secretion to ADP.  
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Adrenaline 
Adrenaline stimulates aggregation through the α2A-adrenoreceptor, which is coupled to 
the Gi family of heterotrimeric G proteins. Since this is the same family of G proteins 
that is regulated by the P2Y12 ADP receptor, it is important to compare responses to 
adrenaline and ADP in patients that have a defect in one or both of these agonists, 
although it should be borne in mind that studies in mice have demonstrated major roles 
for distinct Gi isoforms in signalling by the two receptors (Jantzen et al., 2001, Yang et 
al., 2000).  Specifically, P2Y12 is coupled to Giα2 and the α2A-adrenoceptor is coupled 
to Gz.  The response to adrenaline is characterized by the absence of shape change and 
a biphasic aggregation in which the second phase occurs concomitantly with release of 
dense granules as indicated by release of ATP (Figure 3.18). Importantly, this phase of 
aggregation and secretion are completely blocked in the presence of indomethacin 
(Figure 3.18). In contrast, blockade of the P2Y1 ADP receptor has a relatively mild 
effect on aggregation and secretion to adrenaline that is manifest as a small shift to the 
right in the concentration response curves for the two responses (Figure 3.18). 
Blockade of the P2Y12 ADP receptor by AR-C67085 in this control also inhibits the 
second phase of aggregation and the secretion of ATP.  However, following 
investigation of other controls, I have shown that blockade of the P2Y12 ADP receptor 
can have either a partial or no effect on the second phase of adrenaline-induced 
aggregation, but nevertheless there is always a dramatic reduction in secretion (see 
Chapter 4-Figure 4.2).   
It is important to emphasize that biphasic aggregation to adrenaline was observed in all 
controls that were investigated in this study in view of reports in the literature that a 
proportion of the population exhibit only primary wave aggregation. For example, 
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Weiss and Lages observed secondary aggregation to adrenaline in 117 out 130 donors 
i.e. approximately 90% of donors (Weiss and Lages, 1988). The explanation as to why 
all of the donors in the present study were found to undergo secondary aggregation to 
adrenaline may be because we allowed aggregation to proceed for several minutes, as 2 
of the 60 controls exhibited a delay in the secondary phase, which took more than 5 
minutes to be begin as illustrated in Figure 3.19. Indeed, I have investigated one of 
these two controls on five separate occasions and each time have observed a prolonged 
delay in the onset of the second wave.   
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Arachidonic acid and the thromboxane mimetic U46619 
Arachidonic acid is converted to TxA2 by platelet cyclooxygenase, which induces 
platelet activation through the Gq and G13-coupled thromboxane receptor. TxA2 has a 
very short half-life and so the stable analogue, U46619, was used to induce platelet 
activation through the thromboxane receptor under in vitro conditions.  
 
Arachidonic acid was observed to induce biphasic aggregation at low concentrations 
and monophasic aggregation at higher concentrations, along with robust secretion 
(Figure 3.20).  Powerful, sustained aggregation and secretion were abolished in the 
presence of indomethacin, although there was a residual shape change response and 
weak aggregation as discussed above in Section 3.3.5 and consistent with the results of 
Frelinger et al (Frelinger et al., 2006).  In comparison, the P2Y1 ADP antagonist, 
MRS2179, has a minor inhibitory effect on aggregation and ATP secretion to low but 
not high concentrations of arachidonic acid, while the P2Y12 ADP antagonist, AR-
C67085, reduced the second component of aggregation, although the extent of this 
reduction varied between controls.   The P2Y12 ADP antagonist, AR-C67085, also 
partially inhibited ATP secretion (Figure 3.20). Thus, arachidonic acid mediates full 
aggregation and secretion through a synergy between the thromboxane receptor and the 
P2Y12 ADP receptor, but at high concentrations it can partially overcome the effect of 
P2Y12 ADP receptor blockade. In addition, arachidonic acid stimulates shape change 
independent of thromboxane formation.  
 
Strikingly, the effect of the above inhibitors on the response to U46619, a stable 
analogue of TxA2, was distinct from that observed against arachidonic acid (Figure 
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3.21). In particular, aggregation and secretion induced by U46619 was not altered, or 
was only marginally reduced, in the presence of indomethacin (Figure 3.21). On the 
other hand, the second phase of the aggregation response and the stimulation of 
secretion by U46619 were partially inhibited in the presence of the P2Y12 receptor 
antagonist, AR-C67085, as was the case for arachidonic acid. The P2Y1 receptor 
antagonist, MRS2179, has a very minor effect on the response to low but not higher 
concentrations of U46619 (Figure 3.21), as was the case with arachidonic acid.  This 
minor effect is presumably because of redundancy in that the TxA2 and P2Y1 receptor 
signal through the same pathway and the former is expressed at approximately one 
order of magnitude higher level.  Thus, comparison of responses to arachidonic acid 
and U46619 allows differentiation between a defect at the level of platelet 
cyclooxygenase or the platelet thromboxane receptor. Specifically, platelet activation 
by arachidonic acid is inhibited in the presence of the cyclooxygenase inhibitor 
indomethacin, whereas the response to U46619 is not. On the other hand, the response 
to both stimuli would be inhibited by a defect in the thromboxane receptor.  
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PAR1 and PAR4 peptides 
The ability of the thrombin receptors, PAR1 and PAR4, to mediate platelet activation 
can be monitored using thrombin receptor activating peptides (TRAPs) that are specific 
for each receptor (Coughlin, 2005). In the present study, we have used SFLLRN and 
AYPGKF to activate PAR1 and PAR4, respectively. Both thrombin receptors are 
coupled to Gq and G13 heterotrimeric G proteins. The two PAR1 and PAR4-specific 
peptides induce similar patterns of aggregation and secretion and their responses are 
altered in a similar way in the presence of indomethacin and the P2Y12 receptor 
antagonist. For both peptides, the P2Y1 receptor does not appear to contribute to 
aggregation or secretion, presumably because of redundancy in their signalling 
pathways as is the case for the thromboxane receptor (Figures 3.22 and 3.23). On the 
other hand, the sustained aggregation induced by intermediate concentrations of the 
PAR1 and PAR4-specific peptides is converted to a transient response in the presence 
of indomethacin and the P2Y12 receptor antagonist, AR-C67085, with a corresponding 
decrease in dense granule secretion (Figures 3.22 and 3.23). Higher concentrations of 
the two peptides induce sustained, maximal aggregation in the presence of 
indomethacin and AR-C67085, although dense granule secretion is reduced. Thus, 
these results demonstrate that platelet activation by the PAR1 and PAR4-specific 
peptides is reinforced by release of TxA2 and secretion of ADP, and that this is most 
readily seen at intermediate concentrations of the two peptides.  
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Collagen and CRP 
Collagen initiates platelet activation through the two glycoprotein receptors, GPVI and 
integrin  α2β1 (Nieswandt and Watson, 2003). Crosslinking of GPVI generates 
powerful tyrosine kinase-dependent signals that mediate activation. In addition, the 
interaction of collagen with GPVI is reinforced by binding to integrin α2β1, thereby 
part of the function of the integrin is to increase binding to GPVI. Integrin α2β1 also 
generates weak tyrosine kinase-based intracellular signals, although the significance of 
these is not known (Inoue et al., 2003). The synthetic collagen, CRP, induces platelet 
activation independent of integrin α2β1 and can therefore be used to distinguish 
between defects in GPVI and α2β1. The ability of a low concentration of collagen to 
induce full aggregation and dense granule secretion is markedly inhibited in the 
presence of indomethacin and by the two ADP receptor antagonists, MRS2179 and 
AR-C67085 (Figure 3.24). This demonstrates the critical role of the two ADP receptors 
and thromboxane formation in mediating platelet activation to low concentrations of 
collagen. In comparison, the P2Y1 receptor does not contribute to activation by higher 
concentrations of collagen (Figure 3.24). On the other hand, aggregation and ATP 
secretion to higher concentrations of collagen is powerfully inhibited in the presence of 
indomethacin, whereas blockade of the P2Y12 receptor has a less marked inhibitory 
effect (Figure 3.24). Thus, these results demonstrate that platelet activation to collagen 
is critically dependent on generation of thromboxanes and, to a lesser extent, the P2Y12 
receptor.  This can be explained by the fact that only a small proportion of platelets 
undergo adhesion to collagen and it is the release of the two secondary mediators that 
mediate activation of other platelets, especially at lower concentrations of collagen.  
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In comparison, responses to all concentrations of CRP are independent of the P2Y1 
receptor and have only a partial dependency on liberation of thromboxanes and the 
P2Y12 receptor (Figure 3.25). Thus, a high concentration of CRP is able to induce full 
aggregation in the presence of indomethacin and AR-C67085, although dense granule 
secretion is partially reduced. Indomethacin and AR-C67085 cause a greater level of 
inhibition of aggregation and ATP secretion to an intermediate concentration of CRP 
(Figure 3.25). Thus, responses to CRP and collagen can be distinguished in terms of 
their dependency on thromboxanes and the P2Y12 ADP receptor. The ability of CRP to 
induce powerful activation that is largely independent of secondary mediators is 
important in the context of testing whether there is a generalized defect in platelet 
responses or a defect that is restricted to activation mediated through G protein coupled 
receptors or dense granule secretion. Further, the use of CRP and collagen is important 
in distinguishing between patients with defects in the two collagen receptors, GPVI 
and integrin α2β1.  The response to CRP is also more heavily influenced by a reduction 
in the density of GPVI, as shown in mouse studies, because its ability to crosslink the 
receptors is the product of its (low) affinity for GPVI and avidity, whereas for collagen, 
the increased affinity for integrin α2β1 reduces the reliance on receptor density.  
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3.4 Discussion 
 
Born-aggregometry is the most widely used test in clinical research for investigating 
patients with suspected platelet-based bleeding disorders. Despite this, there are no 
established guidelines on how to perform these studies, with practices varying widely 
both within and between countries (Zhou and Schmaier, 2005, Moffat et al., 2005, 
Cattaneo et al., 2009). Further, the interpretation of aggregation traces is complex and 
hampered by the relatively few patients that are sent for testing. There have also been 
surprisingly few changes in recent years in the way that aggregation testing is 
performed in the laboratory, especially in light of our increased understanding of the 
mechanisms that underlie platelet activation. As a consequence, the majority of clinical 
laboratories are unclear on many aspects of Born-aggregometry, such as agonist 
selection, agonist concentration and whether to correct for platelet number etc. This 
has naturally led many clinical laboratories to consider whether other tests are more 
appropriate in analysing platelet function and to question the usefulness of aggregation 
in identifying conditions other than severe defects in platelet function such as those 
seen with Glanzmann Thrombasthenia or Bernard Soulier Syndrome.  
 
The goal of the work in this chapter was to investigate the reproducibility of 
aggregation responses to platelet agonists within a population of healthy volunteers and 
to establish the dependency of response on factors such as platelet count, time after 
donation and individual donor variation. In parallel, simultaneous measurement of 
ATP secretion from dense granules using a lumi-aggregometer has demonstrated that 
measurement of both parameters provides valuable information on the effect of 
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inhibition of the two major feedback mediators, ADP and TxA2, on platelet activation. 
The data generated during this work are an important resource of information to aid in 
testing of platelet samples. Importantly, the study demonstrates that aggregation and 
secretion responses are relatively robust within a population of healthy volunteers over 
the range of platelet concentrations that are found within healthy volunteers (150–600 
x109 platelets/litre) and that there is no major variation in response curves with sex, age 
or platelet number over defined ranges. The work also demonstrates that platelet 
activation is maintained over several hours when PRP is stored at room temperature or 
as whole blood. In comparison, many clinical testing laboratories in the UK dilute the 
PRP to a constant platelet concentration, usually 200 x 109/litre, and attempt to 
complete the study within 2 hours in line with guidelines of the British Society of 
Haematology Task Force (BCSH, 1988). Not only does this impose significant 
constraints on the number of agonists that can be tested, there is now evidence that 
dilution of samples with PPP can modify aggregation (Lecchi, 2005, Cattaneo et al., 
2007, Mani et al., 2005). However, in the case of thrombocytopenic donors, where the 
platelet count is less than 150 x 109 platelets/litre, aggregation is impaired and so there 
is a need to either dilute the PRP from the control donor to the same count or to use 
washed platelets in order to increase the platelet concentration.  
 
Although the present standard curves are a powerful resource of information, it should 
be stressed that each clinical laboratory should generate their own standard 
concentration response curves from within a population of healthy individuals because 
of the potential impact of subtle differences in methodology. It is also recommended 
that studies are performed on a healthy volunteer alongside those on a patient to 
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control for any untoward experimental difficulties. Inherent in the use of a control 
volunteer in this way, however, is the possibility that the volunteer’s platelets may not 
appear normal, possibly because of unknown ingestion of a platelet modifying agent or 
because of donor-specific differences in the concentration-response relationships. For 
example, the present work has described donor-specific concentration response 
differences to ADP which are maintained over time. Nevertheless, the availability of 
reference curves such as those generated in this work provides confidence on the 
response within a healthy donor for a particular agonist.  
 
The experiments with the P2Y1 and P2Y12 ADP receptor antagonists and the 
cyclooxygenase inhibitor indomethacin provide important information on the distinct 
roles of these pathways in mediating platelet aggregation and secretion to different 
platelet agonists. This is important in helping to diagnose a patient with platelets which 
exhibit a defect in response to more than one of the conventional platelet agonists, 
especially as a defect in the generation of either of these feedback agonists is 
anticipated to be a common cause of mild bleeding (given their critical roles in 
supporting platelet activation). Significantly, in many cases, the effect of inhibition of 
P2Y1 and P2Y12 ADP receptors or cyclooxygenase is only revealed by analysis of 
responses to low/intermediate concentrations of agonists, thereby emphasizing the 
importance of studying multiple agonist concentrations. This is pertinent in the context 
that testing in some but not all clinical laboratories is restricted to a single 
concentration of an agonist. Further, it is anticipated that these reference profiles will 
facilitate distinguishing of patients with defects in the two P2Y1 and P2Y12 ADP 
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receptors from those with a ‘secretion disorder’, as only the former are characterized 
by a loss of response to ADP. 
 
The present work has investigated the concentration response relationships for a 
number of platelet agonists, several of which are not routinely used in clinical 
laboratories, namely the stable thromboxane mimetic, U46619, the synthetic collagen, 
CRP, and PAR1 and PAR4 specific peptides. Investigation of the effect of CRP 
provides important information on whether a loss of response to collagen is mediated 
at the level of GPVI or integrin α2β1. A partial defect in GPVI would only cause a 
small reduction in response to collagen because of the presence of integrin α2β1, 
whereas it would have a much more dramatic effect on the response to CRP as shown 
by studies on mouse platelets that express a reduced level of GPVI (Snell et al., 2002). 
The use of U46619 provides important information on whether a diminished response 
to arachidonic acid is mediated at the level of cyclooxygenase or through the 
thromboxane receptor. The PAR-specific peptides would identify defects in the two 
thrombin receptors, PAR1 and PAR4. Indeed, the fact that these two PAR-specific 
peptides are not routinely tested in most clinical laboratories may explain why, as yet, 
no patients with defects in PAR1 and PAR4 have been described. 
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3.5 Conclusion 
 
The present observations serve to demonstrate the robustness of platelet aggregation 
and secretion over a range of parameters and also emphasise the known benefit of 
simultaneous monitoring of ATP secretion as a marker of dense granule release. The 
generated response relationships and patterns of aggregation are an important resource 
for the clinical laboratory in the testing of patients. The results also demonstrate the 
importance of using additional agonists, such as the two PAR-specific peptides, in the 
routine testing of patients, especially those with a clinical history suggestive of a 
platelet disorder but where a defect has not been found. The further development and 
refinement in the use of aggregation testing and coanalysis of ATP secretion is likely 
to increase the diagnosis of patients with mild, platelet-based bleeding disorders. This 
increase in testing will require extra resources, but in the long term will benefit both 
the patient and the clinic. 
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4.1 Aim 
 
A proportion of patients with mild bleeding that is believed to be due to platelet 
dysfunction are expected to have quantitative and/or qualitative defects in the platelet 
ADP receptor P2Y12. This would be consistent with the major feedback role of ADP in 
potentiating platelet activation through the P2Y12 receptor and the recent identification 
of several patients with defects in the receptor. The overall aim of the work in this 
chapter was to search for patients with defects in the P2Y12 ADP receptor using two 
distinct approaches: 
(i) monitoring of aggregation and secretion in patients with platelet 
dysfunction. 
(ii) sequencing of the P2Y12  receptor in the 152 index cases with type1 VWD 
from the EU MCMDM-1VWD study coordinated in the University of 
Sheffield. 
 
4.2 Introduction 
 
Patients with a severe bleeding problem caused by a platelet dysfunction such as 
Glanzmann Thrombasthenia, Bernard Soulier syndrome or marked thrombocytopenia 
are usually identified early in life. However, patients with a mild bleeding disorder that 
is due to platelet dysfunction often remain undiagnosed until early adulthood or later 
because the individual may not have been exposed to an appropriate haemostatic 
challenge such as a tooth removal or minor surgery. The majority of these patients will 
have a history of excessive bruising and/or nose bleeds, but similar symptoms are 
found in healthy individuals and so on their own are not diagnostic.  
 139
 
Chapter 4 – Search for P2Y12 receptor defects 
Surprisingly few patients have been identified with inherited, genetically-
mapped mutations in the collagen receptor GPVI, the major ADP receptor, P2Y12, and 
the TxA2 receptor as summarized in Table 4.1. Moreover, none of these patients are 
from the UK.  Perhaps even more striking is the observation that no patient has been 
described with a bleeding disorder that is attributed to a defect in either of G protein-
coupled receptors for thrombin, PAR1 and PAR4, or the ADP P2Y1 receptor, despite 
evidence from mouse studies demonstrating that PAR4 and P2Y1 contribute to platelet 
activation in vivo (mice platelets do not express PAR1).  The difficulty in identifying 
patients with defects in these receptors is likely to be the consequence of the mild 
nature of the bleeding disorders and current limitations in platelet testing in the clinic, 
although it must also be borne in mind that defects in some of these receptors may not 
cause excessive bleeding in human due to redundancy.  
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In the present chapter, I used the reference concentration response curves for 
aggregation and ATP secretion described in Chapter 3 to search for patients with 
defects in the P2Y12 ADP receptor.  This work was undertaken as ‘proof-of-principle’ 
that more extensive use of platelet lumiaggregometry would facilitate diagnosis of 
platelet disorders.  The P2Y12 ADP receptor was chosen as the focus on this work 
because several patients with mild bleeding linked to mutations in this receptor have 
been identified.  As a result of these studies, several patient samples were sent for 
genomic DNA sequencing of P2Y12 to the laboratory of Dr. M. Daly in the University 
of Sheffield (see Appendix 2).  
Alongside this approach, the P2Y12 receptor gene was sequenced by Dr. Daly 
in 148 of the 152 index cases enrolled in the MCMDM-1VWD study (Goodeve et al., 
2007). Given the role of VWF in primary haemostasis, and the similarities in clinical 
phenotypes of patients with type 1 VWD and platelet-based bleeding disorders, it is 
possible that the bleeding tendency in patients diagnosed with type 1 VWD is 
influenced by defects in one or more platelet receptors.  The P2Y12 ADP receptor was 
again chosen as ‘proof-of-principle’ for this hypothesis. This approach identified two 
heterozygous mutations in P2Y12 and I was fortunate in that one of the index cases, 
along with several family members, were located in greater Birmingham and were 
available for further testing. 
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4.3 Results 
 
4.3.1 The effect of the P2Y12 receptor antagonist, AR-C67085, on platelet 
activation by ADP and adrenaline 
The P2Y12 ADP receptor and αA-adrenoceptor signal via the Gi family of G proteins, 
albeit through distinct Gi α-subunits, namely Gαi2 and Gz, respectively, at least as 
shown using mouse platelets (Jantzen et al., 2001, Yang et al., 2002).  Thus, signalling 
defects that lie downstream of Gi should result in reduced responses to both agonists.  
Further, there is also evidence from the studies through the use of P2Y1 and P2Y12 
receptor antagonists that ADP plays an important feedback role in platelet activation to 
adrenaline through both receptors, as reported in Chapter 3 and described in more 
detail below.   
 
  The effect of the P2Y12 receptor antagonist, AR-C67085, on the response to a 
concentration of ADP (10 μM) that induces sustained aggregation in over 60 controls 
was evaluated.   AR-C67085 has no effect on shape change, which is mediated through 
the P2Y1 receptor, but induces a transient aggregation response that returns to the base-
line within 2 minutes. The trace in Figure 4.1 is representative of the response in over 
10 controls and demonstrates the critical role of the P2Y12 ADP receptor in mediating 
sustained aggregation. In contrast, AR-C67085 had not effect on the primary wave of 
aggregation to adrenaline but caused a slight but significant reduction in the second 
phase of the response which was associated with a dramatic reduction in secretion 
(Figure 4.2).  
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4.3.2 ADP and adrenaline aggregation in a patient with Hermansky-Pudlak 
syndrome  
The role of dense granule secretion in the aggregation response to ADP and adrenaline 
was further investigated in two related patients with a newly identified form of 
Hermansky-Pudlak syndrome (HPS-8) caused by a base pair deletion in a gene 
BLOC1S3  that encodes for a dense granule protein (Morgan et al., 2006).  Full 
sustained aggregation was noticed in response to ADP (10 μM) whereas only a primary 
wave of aggregation was observed in response to adrenaline (10 μM) in both patients 
(Figure 4.3). 
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 4.3.3 Patients with Gi-like defect 
Over the course of four years, we investigated patients who had been clinically 
diagnosed with a platelet defect by the consulting consultant.  The majority (>60%) of 
these patients were referred by Dr Jonathan Wilde from the Queen Elizabeth Hospital, 
but we also received over ten patients each from the clinics of Drs Makris and 
Mumford in Sheffield and Bristol respectively, as well as one or two patients from 
other consultants, including Dr Mike Williams in the Birmingham Children’s Hospital 
and Dr David Keeling in Oxford.  The majority (90%) of the patients had been 
previously investigated in the clinic.  The vast majority of the patients that had 
previously investigated had not been found to have any evidence of a coagulation 
defect or type 1 VWD, and most had been shown at least a partial defect in platelet 
aggregation to ADP.  The patient selection was therefore intentionally biased towards 
patients with a decrease in aggregation to ADP consistent with the primary goal of 
searching for defects in the P2Y12 ADP receptor.  However, patients categorized with 
other platelet defects such as storage pool disease or a cyclooxygenase defect were also 
included, in part because of difficulty in diagnosing such disorders. 
Within the group of 80 index patients that were investigated in this study, 14 
unrelated patients had a combined defect in aggregation to both ADP and to adrenaline, 
while a further patient (Birm-JW-100708) showed a selective defect in response to 
ADP as described in further detail in section 4.3.4 below.  Importantly ATP secretion 
in response to a high concentration of collagen related peptide (CRP) in these patients 
was within the normal range thereby ruling out a dense granule defect. All of these 
patients also had reduced aggregation to low concentrations of other agonists, but these 
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were attributed to the reduced response to ADP and so are not described in further 
detail. 
Given that ADP, through the P2Y12 receptor, and adrenaline signal via the Gi 
family of heterotrimeric G proteins, this group of patients have therefore been 
categorized with a ‘Gi-like defect’.  In this context, it is important to remember that, in 
mouse platelets, the P2Y12 receptor and adrenaline have been shown to signal via 
distinct Gi family G proteins, namely Giα2 and Gz, respectively (Yang et al., 2000, 
Yang et al., 2002), although it is not known if this is the case in humans.  There is 
however a residual component of signalling by both receptors in mice platelets that is 
independent of Giα2 and Gz, and also of Giα3, thereby implicating Giα1 in signalling by 
both receptors.  There may also be a difference in the coupling of the two receptors to 
Gi proteins between human and mouse, which may explain why adrenaline is unable to 
induce aggregation in mouse platelets.  
Patients with a ‘Gi-like’ defect were further subdivided into two groups dependent 
on the presence of partial or complete absence of primary wave aggregation to 
adrenaline.  Thus Group 1 (9 patients) showed a reduced primary wave and no second 
wave of aggregation to ADP and to adrenaline as illustrated in Figure 4.4.  Group 2 (5 
patients) showed a partial/complete loss of the second wave of aggregation to ADP and 
a complete loss of both the primary and secondary wave to adrenaline as illustrated in 
Figure 4.5.  
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The complete abolition of aggregation to adrenaline in Group 2 could be explained by 
a mutation in the α2-adrenoceptor, but this does not account for the associated loss of 
response to ADP.  Studies were therefore undertaken to investigate whether adrenaline 
was still able to synergise with other platelet receptor agonists and to inhibit the 
formation of cAMP in the patient’s platelets.  As shown in Figure 4.5, at a 
concentration that had no effect on aggregation, adrenaline (10 μM) converted the 
response to the PAR1 peptide (10 μM) from a transient to a maximal, sustained 
aggregation, with a similar result being observed in the other 4 patients that were 
investigated from this group.  To investigate the effect on inhibition of cAMP 
formation, platelets were treated with PGE1, which elevates cAMP formation through 
the prostacyclin receptor (Moncada et al., 1976, Miller and Gorman, 1976, Gorman et 
al., 1978), in the absence or presence of ADP / adrenaline. The ability of the two Gi-
coupled receptor agonists to inhibit formation of cAMP was initially assessed in 8 
healthy controls as shown in Figure 4.6. ADP and adrenaline decreased the level of 
cAMP by 62.66 ± 13.78 and 50.16 ± 14.62, respectively (Figure 4.6).  Both adrenaline 
and ADP suppressed the elevation of cAMP by PGE1 to a similar extent to that seen in 
controls in the two available patients who failed to give primary wave aggregation as 
illustrated in Figure 4.7. These results therefore demonstrate that the α2-adrenoceptor is 
still able to signal in this group of patients, despite in its inability to induce primary 
wave aggregation, consistent with the associated impairment in aggregation to ADP. 
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Although both of these groups of patients showed defects in response to ADP and to 
adrenaline, we chose to sequence the P2Y12 gene from three patients in Group 1 and 
three in Group 2 in view of the possibility that the defect was due to a feedback role of 
ADP in platelet activation by adrenaline.  In this context, it is important to emphasize 
that the effect of P2Y12 blockade on adrenaline induced aggregation varies between 
controls as described in Chapter 3 and discussed further below.  Samples were sent to 
Dr. Martina Daly at Sheffield University for sequencing of P2Y12 gene.  No genetic 
mutations in the encoding region of the gene was found in the six samples that were 
analysed, with three from each of the two groups. 
 
4.3.4 A Patient with homozygous P2Y12 receptor mutation 
As discussed above, one of the patients that was investigated in this study, coded Birm-
JW-100708, exhibited a selective defect to ADP whereas the response to adrenaline 
was normal.  Birm-JW-100708 was a 31 year old Asian female with a life long history 
of bruising and prolonged bleeding from cuts, and who had exhibited excessive 
bleeding following a caesarean section. Her parents were first cousins, although neither 
had a history of bleeding. The brother of Birm-JW-100708 also had a life long history 
of prolonged bleeding from cuts, but was not available for investigation.  The full 
blood count and coagulation tests in patient Birm-JW-100708 were within the normal 
range.  
The platelets from patient Birm-JW-100708 exhibited a marked defect in 
response to all concentrations of ADP, which was manifest as a weak, transient 
aggregation response and abolished ATP secretion to a concentration of 100 μM 
(Figures 4.8 and 4.9). On the other hand, shape change induced by ADP was retained 
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and the platelets exhibited a normal pattern of biphasic aggregation to adrenaline 
(Figure 4.8).  A reduction in magnitude and transient aggregation response of this 
nature is indicative of a defect in the P2Y12 rather than the P2Y1 ADP receptor, which 
mediates shape change (see chapter 3). Consistent with this, the ADP receptor 
antagonist, AR-C67085 (1µM), reduced the aggregation response in the control to the 
same level as that seen in the patient, whereas it had no effect on the response of the 
patient (Figure 4.8).  Furthermore, ADP was unable to inhibit formation of cAMP 
levels in PGE1-stimulated platelets in the patient, whereas adrenaline induced marked 
suppression in formation of the second messenger (Figure 4.10).  ADP and adrenaline 
both inhibited formation of cAMP in platelets from a control performed alongside 
(Figure 4.10). 
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The patient’s platelets exhibited a defect in aggregation to other platelet agonists, 
which was consistent with defect in the P2Y12 receptor.   Thus, for example, there was 
a blunted aggregation response to collagen at low concentrations of the matrix protein 
(Figure 4.8).  On the other hand, the level of ATP secretion from the dense granules 
induced by maximal concentrations of all agonists other than ADP fell within the 
normal range indicating that the reduced aggregation was not due to a defect in 
secretion (Figure 4.9).   
The above observations suggest a defect at the level of the P2Y12 ADP receptor. 
DNA from the patient was therefore sent for sequencing, which was performed by Dr 
Martina Daly in Sheffield.  Genomic DNA sequencing revealed that the patient was 
homozygous for a single base deletion at nucleotide position 36 in the coding sequence 
of P2Y12.  This mutation is predicted to cause a frame shift and introduction of a 
premature stop codon (c.36delG, p.Gly12fs).  This mutation therefore predicts a 
complete failure of P2Y12 receptor expression.  
 
4.3.5 Patient with a heterozygous P2Y12 receptor mutation 
A second approach that used to search for patients with a defect in the P2Y12 gene was 
to sequence the gene (consent was obtained) in the 152 index cases enrolled in the EU 
MCMDM-1VWD study that was led by Drs Ian Peake and Anne Goodeve in Sheffield 
(Goodeve et al., 2007).  The sequencing was coordinated by Dr Martina Daly.  This 
approach identified two index cases with heterozygous mutations that predicted a 
lysine to glutamate mutation at amino acid position 174 (K174E) in the second 
extracellular loop, and a proline to alanine at position 341 (P341A) which lines in a 
putative PDZ binding domain at the C-terminus of the receptor.  The index case with 
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the K174E mutation, and several family members, live in the Birmingham area and 
was available for further experimentation.  The second index case and his relatives 
were from Milan and so were not available to me for experimentation. 
The index case (PII.1) with the K174E mutation was heterozygous for a A>G 
transition at nucleotide 520 of the P2Y12 cDNA (where +1 is the A of the initiator ATG 
codon).  This mutation predicted substitution of lysine by glutamate at amino acid 
position 174 (520A>G; K174E) which is located in the second extracellular domain 
adjacent to the cysteine which is covalently modified by clopidogrel.  The 520A>G 
alteration did not occur in 80 unrelated healthy control subjects (160 alleles) recruited 
in the same centre as PII.1, supporting the likelihood that this mutation was 
functionally relevant rather than a novel polymorphism. 
The family tree shown in Figure 4.11 reveals the distribution of P2Y12 receptor 
mutation alongside the mutation in the VWF gene that was also found in the index case 
(Figure 4.11).  The mother of the index case, PII.1, was heterozygous for the mutation 
in the P2Y12 receptor but not the VWF gene, even though she had one of the highest 
bleeding scores in the family. The bleeding score (a quantitative measure of bleeding) 
of each of the members of the family is also shown and is based on the questionnaire 
used in the EU study (which can be found in the Appendix). The bleeding symptoms 
were recorded retrospectively for all subjects using the questionnaire to derive the 
bleeding score and for each individual, a summative bleeding score was computed as 
the sum of each symptom-specific grading, and could theoretically range from - 3 (no 
spontaneous bleeding symptom, no bleeding after surgeries, teeth extractions and 
deliveries) to +45 (major bleeding for all symptoms), a value greater than 3 being 
considered abnormal (Tosetto et al., 2006).      
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The index case, PII.1, and two relatives who also carried the K174E mutation, namely 
her mother (PI.1) and sister (PII.2), were available for assessment of platelet function. 
Platelets from all three subjects underwent shape change in response to stimulation by 
ADP over the concentration range of 3 – 30 μM (Figure 4.12), which is mediated 
through activation of the P2Y1 ADP receptor. In contrast, platelets from the three 
patients exhibited reduced and transient aggregation to a concentration of ADP (10 
μM) that induced maximal, sustained aggregation in samples from over 60 control 
subjects that were analysed over the period of the last four years, including the control 
who was investigated on the day of the experiment (Figure 4.12 and Chapter 3 Figure 
3 .12). There was also a reduction in response to a lower concentration of ADP (3 μM) 
relative to controls, whereas a higher concentration of ADP (30 μM) induced maximal, 
sustained aggregation in all three patients with P2Y12 receptor gene mutation (Figure 
4.12). These findings therefore demonstrate a partial defect in the P2Y12 receptor. 
Consistent with this, the P2Y12 receptor antagonist, AR-C67085, caused a further 
reduction in the response to ADP (10 μM) such that, in the presence of the P2Y12 
receptor antagonist, the platelets from the patients and control showed a similar 
response (Figure 4.12). The partial nature of the defect in the response to ADP was 
further illustrated by the reduction in the level of dense granule secretion induced by 
ADP, as monitored by measurement of ATP release using luciferin-luciferase in one of 
the three patients in which this study was performed (Figure 4.13). Thus, the presence 
of the heterozygous K174E mutation induces a partial loss in aggregation and secretion 
to ADP.  
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The aggregation of platelets from the index case and PI.1 to other agonists was also 
examined. Sustained aggregation was observed in platelets from both the index case 
and PI.1 in response to high concentrations of CRP (1 μg/ml), collagen (3 μg/ml), 
PAR-1 peptide (100 μM), PAR-4 peptide (500 μM) and U46619 (3 μM) as shown by 
the example traces in Figure 4.12.  In contrast, reduced aggregation responses to lower 
concentrations of the above agonists were observed in the patient, consistent with a 
positive feedback role for ADP. An approximate 50 % reduction in ATP secretion was 
observed in response to high concentrations of the above agonists in the two patients 
with the exception of CRP as illustrated by the example traces in Figure 4.14.  
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A series of further studies were performed to further characterize the defect.  The 
ability of ADP to inhibit cAMP levels in the PGE1-stimulated platelets was within the 
normal range in these heterozygous patients (Figure 4.15). This shows that cAMP 
assay is not sufficiently sensitive to detect heterozygous function disrupting mutations 
in P2Y12 receptor. The binding of [3H]2MeS-ADP to the P2Y12 receptor in platelets 
from two affected individuals was reduced by 50% relative to controls that were 
analysed at the same time, while binding to the K174E mutant in a transfected cell line 
was abolished despite a similar level of surface expression to that of the wild type 
receptor (Figures 4.16 and 4.17).  The binding and cell line studies were performed by 
Dr Stuart Mundell in Bristol.  
Together these results demonstrate that the K174E mutation causes a marked 
inhibition in the binding of ADP to the P2Y12 ADP receptor.  
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4.4 Discussion 
 
In this Chapter, two approaches were used to search for mutations in the P2Y12 ADP 
receptor in patients with a clinically diagnosed bleeding disorder.  The first involved 
the functional characterization of platelets from patients registered at Haemophilia 
Care Centres throughout the UK, with the majority from the Birmingham Queen 
Elizabeth Hospital, combined with targeted gene sequencing of selected individuals. 
Eighty patients were studied over the course of this thesis in this way.  The initial 
functional test was that of lumi-aggregometry, but where appropriate, other tests were 
performed, including measurement of cAMP levels in PGE1-stimulated platelets.  This 
test is diagnostic for defects in Gi-coupled receptors. This approach identified a single 
patient who was homozygous for a base pair deletion that gives to a premature stop 
codon very early on in the coding sequence.  14 other patients were shown to have a 
defect in platelet activation by both ADP and adrenaline thereby pointing towards one 
or more mutations in the Gi-signalling axis.  Sequencing of the P2Y12 ADP receptor in 
six of these individuals failed to identify any mutations in the receptor consistent with 
a defect later in the signalling cascade.   The second approach that was used to search 
for defects in the P2Y12 ADP receptor was that of sequencing of 148 out of 152 index 
cases from the EU MCMDM-1VWD study.  This identified two candidate mutations 
that had not been previously identified as polymorphisms and which were absent in 
approximately 100 controls from the same area as the index case.  Only one of these 
two index cases, along with other family members, was available to me for aggregation 
and other functional studies as they were from the Birmingham area.  This work, 
performed in collaboration with Dr Stuart Mundell in Bristol, has revealed defective 
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platelet activation to ADP as a consequence of impaired binding to the G protein-
coupled receptor. Studies on the other mutation, which was in the PDZ binding domain 
of the receptor, has revealed that this causes an impairment in desensitization and 
resensitisation of the receptor, leading to a net reduction in the surface expression of 
the P2Y12 ADP receptor (Stuart Mundell, unpublished).  Together these studies bring 
the total number of known mutations in the P2Y12 ADP to ten, of which interestingly, 
five are heterozygotes. 
There has been much debate on the use of Born lumiaggregometry in 
diagnosing patients with mild bleeding disorders of platelet aetiology.   In the two 
cases described above, a clear defect in aggregation was observed which was 
characterized by a transient response to an intermediate concentration of ADP (10 μM) 
which was shown to cause full and sustained aggregation in platelets from over 60 
controls.  Interestingly, one of these mutations was heterozygous, thereby emphasizing 
the potential of this approach, if used correctly, to pick up defects in ADP-induced 
platelet activation.  This is particularly relevant in clinical laboratories where 
aggregometry is currently the technique most widely used when investigating patients 
with platelet bleeding disorders. Further, platelets from PI.1 showed a reduction in 
ATP secretion at high doses of agonists like PAR1 and PAR4 emphasizing the 
importance of this approach and suggesting the possibility of a secondary secretion 
defect, which could contribute to the clinical phenotype observed in this individual.  
It is generally held that the mild bleeding defect associated with P2Y12 
deficiency is inherited as an autosomal recessive trait and that the milder abnormalities 
in platelet aggregation and secretion displayed by heterozygous individuals are benign 
(Cattaneo et al., 2003).  The identification of the K174E defect challenges this 
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assumption, a result that is further emphasized by the fact that five out of the ten 
known inherited defects in the P2Y12 receptor are heterozygote.  Interestingly, the 
K174E mutation was identified in an index case that had been diagnosed with mild 
type 1 VWD.  While this is consistent with a growing body of evidence that mild type 
1 VWD is multifactorial in origin (and thereby helping to explain the variable 
heritability of the disease), it is important to emphasise that the mother of the index 
case also carries the K174E mutation and has one of the highest bleeding scores, and 
yet does not have type 1 VWD.  Since not all individuals who are heterozygous for a 
P2Y12 mutation have a clinically diagnosed bleeding tendency, this indicates that the 
mother has a second, unidentified defect.  
The present results have important implications for patients taking antiplatelet 
agents such as the P2Y12-targetted medication clopidogrel or aspirin, as these may 
unmask previously unrecognised defects in platelet activation in the patients and 
thereby give rise to serious bleeds. Thus, just as the expression of a thrombotic 
tendency is determined by the combination of inherited and acquired prothrombotic 
risk factors, the same may apply in this case such that the bleeding in disorders such as 
type 1 VWD (particularly in mild cases) or a P2Y12 deficiency should be considered 
multifactorial in origin.   
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4.5 Conclusion 
 
We identified two novel P2Y12 receptor mutations associated with bleeding tendency, a 
homozygous mutation in an otherwise normal individual and a heterozygous mutation 
in patients with a historic diagnosis of type 1 VWD.  The co-existence of type 1 VWD 
and a P2Y12 receptor has not been previously described.  This studies also emphasizes 
that an ADP receptor defect should be suspected whenever ADP at a concentration of 
10 µM or higher induces a reversible aggregation preceded by a normal shape change. 
Tests such as inhibition of adenylyl cyclase can be used to further specify the condition, 
but genetic analysis will be essential to confirm the defect. The bleeding diathesis 
which is associated with this hereditary defects in the P2Y12 receptor further emphasize 
the critical role of ADP and its signaling pathway in the aetiology of mild platelet-
based bleeding disorders.   
Further functional studies combined with the sequencing of tens of genes is 
required to identify the defects in the other patients who have been grouped together 
with a Gi-like defects.  
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5.1 Summary  
Thromboxane A2 (TxA2) is one of the major secondary mediators that interacts with 
other agonists to mediate powerful aggregation and secretion to ensure robust platelet 
activation at sites of damage to the vasculature. Consistent with this critical role, I have 
observed a defect in platelet activation in response to arachidonic acid in 
approximately 14% of patients diagnosed with platelet dysfunction.  In this chapter, I 
report the characteristics of the defect in platelet activation in these patients and focus 
on two, one of which has an unknown defect in arachidonate metabolism, and a second 
with a novel mutation in the TxA2 receptor.  
 
5.2 Introduction 
 
TxA2 is a key secondary mediator in platelet activation that synergises with other 
agonists including ADP to induce powerful platelet activation. As a consequence, 
defects in the formation of TxA2 or in the function of the TxA2 receptor cause 
impairment in platelet activation.  However, because of redundancy in the mechanisms 
of platelet activation and the fact that we are not continuously exposed to events that 
can give rise to serious bleeds, defects in the thromboxane pathway are predicted to 
give rise to a mild bleeding disorder or to be symptomless, as is illustrated by the fact 
that millions of non-steroidal agents, including aspirin, are taken every day by healthy 
individuals without serious bleeding episodes. Nevertheless, it is accepted that chronic 
administration of aspirin can give rise to excessive bleeding in a small number of 
healthy individuals or those at risk of thrombosis, and indeed the latter is an important 
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risk to benefit consideration in the chronic prescribing of aspirin in this group of 
patients. 
Upon platelet activation, TxA2 is generated through sequential activation of 
cytosolic phospholipase A2 (cPLA2), cyclooxygenase-1, (COX-1; also known as 
prostaglandin H2 synthase) and thromboxane A synthase (TXAS) as shown in Figure 
5.1.  Earlier reports that platelets also contain COX-2 have not been confirmed.  
Activation of cPLA2 is the rate limiting step in this pathway and therefore plays a 
crucial role in the regulation of TxA2 synthesis. Activation of cPLA2 is critically 
dependent on the mobilisation of intracellular Ca2+ from intracellular stores by IP3 and 
is therefore mediated downstream of any receptor that induces activation of 
phospholipase C.  In platelets, the activity of cPLA2 is also increased through 
phosphorylation by mitogen activated protein kinases, although this appears to be a 
relatively minor pathway of regulation (Borsch-Haubold et al., 1995). Activation of 
cPLA2 leads to hydrolysis of the SN2 acyl bond in membrane phospholipids to generate 
arachidonic acid which is then metabolised by COX-1 on intracellular membranes. 
COX-1 is a dual-functioning enzyme, possessing both oxygenase and peroxidase 
activities, which converts arachidonic acid to prostaglandin G2 (PGG2) and then to 
prostaglandin H2 (PGH2). The latter has been shown to cause weak activation of the 
platelet thromboxane receptor but is ordinarily rapidly converted to TxA2 by 
thromboxane synthase which induces powerful activation of the TP receptor. 
Activation of the G protein-coupled TxA2 receptor leads to powerful platelet activation 
through Gq- and G13-regulated signalling pathways (Figure 5.1).  There is also evidence 
that arachidonic acid is able to mediate weak platelet activation independent of its 
metabolism by COX-1 and conversion to the prostanoids (Frelinger et al., 2006). It is 
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presently unclear whether this is mediated directly by arachidonic acid or following its 
metabolism by platelet lipooxygenase to downstream metabolites. However, the weak 
nature of this effect means that it is generally considered to play a non-significant role 
in mediating platelet activation.   
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Patients with an ‘aspirin-like’ defect have been diagnosed in clinic testing laboratories 
ever since the anti-platelet activity of aspirin was first reported just over 40 years ago. 
In a significant number of these cases, the identified defect in activation by arachidonic 
acid has been attributed to the ingestion of aspirin or an alternative non-steroidal anti-
inflammatory, emphasizing the importance of obtaining an accurate drug history prior 
to platelet function studies.  However a significant number of these patients have been 
diagnosed with a defect in platelet cyclooxygenase (Malmsten et al., 1975, Horellou et 
al., 1983, Lagarde et al., 1978, Pareti et al., 1980, Rak and Boda, 1980, Roth and 
Machuga, 1982, Matijevic-Aleksic et al., 1996, Rolf et al., 2009) or thromboxane 
synthase deficiency (Defreyn et al., 1981, Mestel et al., 1980). In all these cases, there 
is impairment in arachidonic acid metabolism leading to reduced TxA2 synthesis. 
However, a causative mutation in either of these enzymes has not been found in any 
patient (Rao, 2003) and it is notable that, with the exception of a recent study (Rolf et 
al., 2009), these references are more than ten years old and the majority appeared prior 
to the sequencing of the two enzymes. 
The prevalence of genetic defects in COX-1, thromboxane synthase and the 
TxA2 receptor was estimated to be approximately one hundred patients worldwide with 
ten of these in the UK (Bolton-Maggs et al., 2006), while a second study states that 
‘approximately 40 cases of haemostatic defects that have been published since the 
early 1970s may be regarded as aspirin-like defect’ (Rolf et al., 2009). In both cases, 
however, the basis of these estimates is unclear and the number of patients is low in 
comparison to the number of patients diagnosed with Glanzmann Thrombasthenia 
where more than 1,000 have been identified worldwide.   
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To date, only two mutations in the thromboxane pathway have been reported, a 
mutation in the TxA2 receptor which was identified in several unrelated Japanese 
families (Hirata et al., 1994) and the second in cPLA2 in a white American male of 
Italian descent (Adler et al., 2008). In the first case, a single amino acid substitution 
(Arg60→Leu) in the first cytoplasmic loop of the TxA2 receptor was reported to give 
rise to an inherited bleeding disorder characterized by a defective platelet response to 
TxA2. One of the first cases to be identified is a 53-year-old man who was referred due 
to excessive bleeding from wounds, gum bleeding and the need for blood transfusion 
after prolonged postoperative bleedings (gasterectomy at age 42 and a removal of a 
urinary stone at age 43). His parents were not consanguineous. No signs of petechiae, 
bruising, ecchymosis, or joint involvement were found on physical examination. The 
platelet (count, size and morphology) and coagulation factors were all within normal 
limits. The mutant receptor expressed in CHO cells showed decreased agonist-induced 
second messenger formation despite normal ligand binding affinity. The original study 
(Hirata et al., 1994) described the mutation of having a dominant pattern of inheritance 
suggesting that the mutation produces a dominant negative TxA2 receptor. This and 
later studies however demonstrated that while platelet aggregation to the stable 
thromboxane mimetic, STA2, was abolished in patients who were homozygous for the 
mutation (shape change was retained; Hirata, Kakizuka et al., 1994), a partial or 
normal response was observed to STA2 in heterozygotes, depending on the parameter 
measured (e.g. platelet aggregation showed a partial defect, second messenger 
formation showed no defect (Fuse et al., 1996, Higuchi et al., 1999).  This argues 
against the idea that the mutant receptor is acting solely as a dominant negative.  
Further, the bleeding history of many of the heterozygote patients has not been 
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reported, making it unclear whether bleeding is inherited in a dominant or recessive 
manner.  For the mutant cPLA2, two heterozygous single base pair mutations and a 
known SNP were found in the coding regions of the cPLA2α gene (p.[Ser111Pro, 
Arg485His]+[Lys651Arg]) in a 45-year-old white American male of Italian descent 
with a life-long history of occult gastrointestinal blood loss and frequent bouts of 
abdominal pain as a child and young adult. Repeated episodes of acute gross 
gastrointestinal bleeding late in his fourth decade and multiple episodes of small bowel 
perforation required 5 surgical interventions between 38 and 45 years of age. Surgical 
exploration of the small intestine and intra operative endoscopy revealed multiple 
recurrent ulcerations. The use of non steroidal anti-inflammatory and corticosteroid 
medications was specifically denied. There was no family history of ulcers (Adler et al., 
2008).  
 
By reference to the concentration response curves for aggregation and ATP 
secretion described in Chapter 3, 11 out of 80 index cases have been classified as 
having a cyclooxygenase like defect, with every reasonable effort having been made to 
rule out the ingestion of aspirin or any other non-steroidal cyclooxygenase inhibitor as 
the causative factor.  Further, in one of these cases, the defect was mapped to a 
heterozygote mutation in the thromboxane receptor.  The phenotype of the 11 index 
cases is described below, with special focus on the patient with a TP receptor mutation 
and a second patient with a suspected COX-1-like defect.  
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5.3 Results  
 
5.3.1 Identification of patients with a COX-like defect  
Over the course of the last four years, I have investigated 80 patients diagnosed with a 
mild bleeding defect by consultants in Birmingham, Bristol, Cambridge and Sheffield.  
Of these, eleven have been classified as having a defect in the thromboxane pathway as 
revealed by a defect in aggregation to arachidonic acid (0.5–1.5 mM) relative to other 
platelet agonists. Additional testing is required to identify patients with a defect in 
cPLA2 but this was not done as part of the initial testing of each patient.  Of these, one 
patient was found to have a partial defect in the response to the stable thromboxane 
mimetic, U46619, which was retained in the presence of the cyclooxygenase inhibitor 
indomethacin thereby pointing towards a defect at the level of the thromboxane 
receptor.  This patient is described in Section 5.3.3 below.  The other ten patients had a 
partial or complete loss of aggregation to arachidonic acid but a normal aggregation 
response to U46619, in line with data in Chapter 3 that activation of platelets by the 
stable TxA2 mimetic is not altered in the presence of indomethacin.  These patients 
also had defective platelet aggregation and secretion to (low) concentrations of several 
other platelet agonists, consistent with the loss of the feedback role of the thromboxane 
pathway.  The nature of this defect is illustrated by series of studies on one of these 
patients, Birm-JW-240108, as described below.   
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5.3.2 Diagnosis of a COX-like defect in the  patient Birm-JW-240108 
The index case was a 50 year old female (Birm-JW-240108) with a clinical history 
indicative of a mild bleeding disorder from early childhood.  This included prolonged 
bleeding from cuts for more than 20 minutes and the need for a blood transfusion 
following tooth extraction in early childhood and later in life following tonsillectomy 
at 34 yr of age.  On the other hand, Birm-JW-240108 had given birth to three children 
by vaginal delivery without the need for a blood transfusion. The platelets from Birm-
JW-240108 were investigated for a platelet defect on two separate occasions, separated 
by an interval of more than one year. On both occasions, Birm-JW-240108’s platelets 
did not respond to 1 mM arachidonic acid whereas the control gave a robust and 
sustained aggregation (Figure 5.2), as was the case in greater than 95% of the other 
controls investigated over the course of this thesis (see Chapter 3). Importantly, the 
response of Birm-JW-240108’s platelets to the stable TxA2 mimetic, U46619, was 
within the normal range (Figure 5.2), thereby localizing the defect upstream of the TP 
receptor i.e. at the level of COX-1 or thromboxane synthase.  Further, the response of 
the patient’s platelets to other agonists was consistent with a defect in arachidonate 
metabolism as determined by comparison to the reference curves determined in the 
presence of indomethacin as described in Chapter 3. For example, ADP (10 μM) 
induced full aggregation followed by deaggregation in Birm-JW-240108’s platelets 
(Figure 5.2) whereas it induced a sustained aggregation response in greater than 98% 
of controls.  However, the addition of indomethacin (10 μM) had no effect on the 
response to ADP in Birm-JW-240108’s platelets, whereas it converted the response to 
a transient aggregation in the control that was studied alongside (Figure 5.2).  A similar 
difference between the response of Birm-JW-240108’s platelets and both to the control 
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that was analysed on the same day or over the course of the last four years was 
observed throughout the dose response curve to ADP (Figure 5.3) and to other agonists 
such as adrenaline, which only induced primary wave aggregation in Birm-JW-
240108’s platelets (Figure 5.2). Further, sustained aggregation, similar to that observed 
in controls was observed in response to single high concentrations of collagen (3 
μg/ml), PAR1 (100 μM), PAR4 peptides (500 μM) and CRP (1 μg/ml), whereas a 
reduced aggregation response was observed to lower concentrations of the above 
agonists, consistent with a positive feedback role for TxA2 (data not shown). To further 
localise the defect, I analysed the response to the COX-1 metabolite PGH2 (3μM) in 
the patient alongside the control.  The response was similar in both cases (Figure 5.4) 
thereby indicating that the defect in Birm-JW-240108’s platelets is in the metabolism 
of arachidonic acid by COX-1.  In line with the above results, ATP secretion from 
dense granules was abolished in Birm-JW-240108’s platelets in response to a maximal 
concentration of arachidonic acid while ATP secretion in response to U46619 was 
similar to the control (Figure 5.5). Furthermore, ATP secretion in response to CRP and 
the PAR1 peptide was also within the normal range (Figure 5.5) thereby ruling out a 
secretion defect.  
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To further investigate the defect in the patient, I measured the conversion of 
arachidonic acid to TxA2 synthesis via a TxB2 ELISA assay, as an indirect measure of 
TxA2 production. The formation of TxB2 was almost abolished in Birm-JW-240108 
platelets, consistent with a COX-1 defect, whereas the response to the control was 
within the normal range (Figure 5.6).   
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The above results point to a defect in COX-1.  To investigate this further, the 
expression level of COX-1 was measured in platelets from Birm-JW-240108 alongside 
six other controls and her daughter (S), who does not have a bleeding defect, by 
quantitative western blotting (Figure 5.7). The level of expression of COX-1 in Birm-
JW-240108’s platelets was similar to that in the controls and in her daughter’s platelets 
(daughter is labeled S in Figure 5.7).  Furthermore a similar result was obtained for 
quantitation of thromboxane synthase by western blotting (Figure 5.7).  Thus, the 
defect in Birm-JW-240108’s platelets does not appear to be due to a reduced level of 
expression of COX-1 or thromboxane synthase.  
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The above results raise the possibility of an underlying point mutation in the coding 
region of COX-1.  To investigate this, the cDNA of COX-1 was generated by reverse 
transcription of RNA isolated from white cells and sequenced.  This work was 
performed by Dr. Jen Spalton in the laboratory.  No defect in the sequence was 
identified (not shown – Appendix-5).   
 
5.3.3 Investigation of a patient with a TxA2 receptor defect 
A 14 year old male, Birm-MW-030408, (labeled as P1) with a significant history of 
recurrent episodes of epistaxis where local effects in nasal blood vessels had been ruled 
out, and with no other haemostatic challenges from surgery and trauma, was referred 
for platelet function testing. The patient’s platelets underwent weak shape change to a 
concentration of arachidonic acid (0.5 mM) that induced full aggregation in a control 
which was analysed alongside, but underwent full, sustained aggregation to higher 
concentrations of the lipid agonist (Figure 5.8).  Importantly, the concentration 
response curve for the control was similar to that in over 50 other controls that have 
been analysed over the course of the last four years as described in Chapter 3.  
Furthermore, the patient also exhibited a marked defect in aggregation to intermediate 
and high concentrations of the stable thromboxane mimetic, U46619 (1–10 μM), with 
reduced aggregation observed at lower concentrations and deaggregation at higher 
concentrations (Figure 5.8). In contrast, U46619 (1–3 μM) stimulated full sustained 
aggregation in a control which was analysed alongside, as is the case in over 50 other 
controls that have been studied throughout the course of this work (see Chapter 3).  
Furthermore, there was no diminution in the aggregation response to U46619 (3 μM) 
following incubation with indomethacin (10 μM) (Figure 5.8), which demonstrate that 
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the defect is independent of COX-1 and thromboxane synthase.  This result therefore 
indicates that the defect is at the level of the thromboxane receptor.  
The aggregation results obtained for the other platelet agonists are consistent 
with a defect in the TxA2 pathway. For example, although a high concentration of ADP 
(100 μM) stimulated maximal aggregation, the response was not sustained (Figure 5.9) 
as is seen in controls treated with indomethacin (10 μM) (see Chapter 3). Loss of the 
secondary wave of aggregation to adrenaline was also observed (not shown). Sustained 
full aggregation, similar to that in controls, was observed in response to high 
concentrations of other agonists including collagen, peptides specific for the thrombin 
receptors, PAR1 and PAR4, and the GPVI collagen receptor agonist CRP (Figure 5.9), 
with a corresponding reduction in response to submaximal concentrations due to the 
feedback role of the thromboxane pathway in platelet activation (not shown).  
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The patient’s platelets also exhibited a reduction in the secretion of ATP from dense 
granules in response to high concentrations of ADP, arachidonic acid and the TxA2 
mimetic, consistent with a defect in the thromboxane receptor (Figure 5.10). On the 
other hand, high concentrations of the two PAR peptides induced a normal level of 
secretion of ATP alongside that of the control that was analysed on the same day and 
by comparison to more than 60 other controls measured on different days (Figure 5.10). 
This therefore demonstrates that the nucleotides levels and the release mechanisms 
from the dense granules are within the normal range, thus ruling out a secretion defect 
in this patient. 
 Together, the aggregation and secretion traces in the patient appear point to a 
partial defect at the level of the thromboxane receptor, therefore compromising the 
ability of the patient’s platelets to respond to both endogenous and exogenous sources 
of TxA2. Furthermore, the patient’s platelets generated a similar level of TxB2 to that of 
the control in the presence of arachidonic acid (1 µM) thereby confirming that the 
phenotype is not due a defect in metabolism (Figure 5.11).  
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5.3.4 Identification of the D304N mutation and further confirmatory tests 
 
In order to search for a possible mutation in the TP receptor, genomic DNA sequencing 
was conducted in Bristol by Dr Andrew Mumford. The patient was found to be 
heterozygote for a candidate mutation of an aspartic acid to an asparagine at position 
304 in the 7th transmembrane region of the receptor (Figure 5.12).   This candidate 
mutation is not present in any of the available databases suggesting that it is not a 
known polymorphism.    
The binding of the TxA2 receptor antagonist [3H]-SQ29548 to fixed platelets 
was measured by Dr. Stuart Mundell at University of Bristol. The platelets were fixed 
in Birmingham and transported to Bristol by courier.  The number of binding sites on 
the platelets from the patient was reduced by approximately 50%, whereas the affinity 
constant was not altered relative to the platelets from the patient’s mother (P3) or to an 
unrelated healthy control (Figure 5.13). These results indicate a defect in either 
receptor expression or ligand binding. To distinguish between these two possibilities, 
the binding of [3H]-SQ29548 to CHO cells stably expressing variant D304N TxA2R 
was investigated.  [3H]-SQ29548 exhibited specific binding to the wild-type TxA2R 
but not to the D304N mutant (Figure 5.14; this work was performed by Drs Stuart 
Mundell, Jen Spalton and Andrew Mumford) thereby demonstrating a defect at the 
level of ligand binding.  
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5.3.5 Investigation of relatives of Birm-MW-030408  
 
Two other members of the family of patient Birm-MW-030408 donated samples for 
investigation, including the father (P2) and the mother (P3). Although the father has no 
history of excessive bleeding, his platelets exhibited a partial defect in aggregation and 
ATP secretion in response to arachidonic acid and U46619 which was similar to that 
seen in his son (figure 5.15). Furthermore, DNA sequencing identified the same 
heterozygous mutation as that in the patient (D304N).  On the other hand, the mutation 
was not found in the mother (P3) even though she has a history of heavy menstrual 
periods.  Further, aggregation and secretion responses to U46619 were similar in the 
mother to that of the control (Figure 5.15).  
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5.4 Discussion  
 
 
In this study, as in several previously conducted studies, patients with suspected 
defects within the TxA2 signaling pathway have been identified. I estimate that 11 (i.e. 
14%) of the patients that I have studied have a ‘COX-like’ defect making this one of 
the most common causes of mild bleeding alongside secretion-like (21%) and a Gi 
signaling (19%) defects. The majority (10 out of 11) of patients with TxA2 signaling 
pathway were categorized as having a defect in arachidonate metabolism, while the 
other patient was identified to have a defect at the TP receptor level. Aspirin-like 
defects in platelets have been described for over 40 years and defective platelet 
cyclooxygenase activity has been proposed as a cause of excessive bleeding by several 
groups but a genetic defect has never been reported.   
Patients with a defect in arachidonate metabolism showed a markedly reduced 
aggregation in response to arachidonic acid, a metabolic precursor of TxA2, but not to 
the stable thromboxane mimetic, U46619. Measurement of TxB2 formation from 
exogenous arachidonic acid confirmed a defect in arachidonate metabolism in a sub-
group of these patients (4) and is a powerful means of confirming the initial diagnosis.  
Interestingly, however, in the one patient from this group who was thoroughly 
investigated, we have been unable to find a change in the level of expression or a 
mutation in the coding region of the two enzymes that convert arachidonate acid to 
TxA2, namely COX-1 or TXAS, thereby indicating an alternative cause.  Importantly, 
this patient has consistently denied taking a known COX inhibitor such as aspirin 
thereby raising the interesting possibility that the defect is in an unknown accessory 
protein that supports the conversion of arachidonate acid to TxA2.  To my knowledge, 
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there are no obvious candidates for such a protein to direct further western blotting and 
sequencing studies and thus further work on this patient will have to wait until the 
costs of sequencing and bioinformatics analysis of whole genomes reaches a level that 
gives ‘value-for-money’ in order to identify candidate gene defects.  In the future, the 
application of whole genome sequencing to the study of patients like this case has the 
potential to reveal new unexpected findings in regard to the mechanisms that give rise 
to platelet activation and thereby potential new targets for development of 
antithrombotics. 
             On the other hand, a heterozygous molecular defect in the one patient who 
exhibited a reduced aggregation and secretion response to both arachidonic acid and 
agonist U44619 was identified in the 7th TM region of the TP receptor, namely an 
aspartic acid to asparagine at position 304 (D304N).  This mutation is in an 
evolutionary highly conserved region in 7 transmembrane receptors, namely a NPXXY 
motif, which maintains hydrogen-bond networks between adjacent transmembrane 
domains, although paradoxically in the case of the TP receptor, the mutation is from an 
aspartic acid (D) back to the evolutionary conserved amino acid, asparagine (N).  
Mutations in this region are known to disturb the receptor function, a result that was 
also found in the case of the D304N mutation by expression of the mutant TP receptor 
in an immortalized cell line model by Dr Stuart Mundell in Bristol.  Importantly, this is 
only the second mutation in the thromboxane receptor to be described in the literature 
and the first in which a bleeding defect has been linked to a heterozygous mutation. 
Interestingly, the heterozygous D304N mutation was also identified in the 
patient’s father even though he does not have a history of excessive bleeding.  
Nevertheless, functional studies revealed a partial defect in aggregation and ATP 
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secretion in response to arachidonic acid and U46619 that was similar to that seen in 
his son. This therefore indicates that this mutation alone is insufficient to explain the 
bleeding diathesis and that the son has second defect that, presumably in combination 
with the TP receptor mutant, gives rise to the mild bleeding diathesis.  It is therefore of 
interest that his mother has a history of heavy periods that could be taken as evidence 
for a very mild bleeding defect.  This study therefore emphasizes that a TP receptor 
defect should be investigated when an impairment in response to arachidonic acid is 
observed.  
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6.1 Summary 
 
 
Mild platelet-based bleeding disorders are a heterogeneous group of disorders with a 
variety of causes and functional consequences. Diagnosis is challenging to both 
clinicians and research laboratories due to the absence of a gold standard test. This 
chapter summarises the results of patients who have been investigated over the course 
of nearly 4 years using aggregation and secretion studies along with other specialized 
tests.     
 
6.2 Introduction 
 
The presence of adequate numbers of normally functioning platelets is essential in 
arresting haemorrhage from an injured blood vessel. Excessive bleeding following a 
haemostatic challenge is the hallmark feature of platelet dysfunction, which can arise 
through defects in surface receptors, signaling proteins, granules contents/release, 
cytoskeletal proteins and platelet procoagulant function. The prevalence of platelet 
disorders is uncertain due to the difficulties in diagnosis with only the more severe 
being recognised (Hayward, 2008). 
In Chapter 3, I described a series of reference curves for aggregation and ATP 
secretion to nine platelet agonists in controls, together with the effect of antagonists / 
inhibitors of the major two feedback pathways on these curves.  The reference curves 
and representative aggregation traces have proven invaluable in the assessment of the 
patient’s platelets and also in confirming that each control, measured on the same day 
as the patient sample, was within the normal range. Further, with available resources in 
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the Birmingham Platelet Group, it has been possible to perform additional, specialist 
tests alongside the aggregation and secretion studies as part of the initial evaluation of 
each patient sample.  
Using this approach, patients have been classified on the basis of the platelet 
phenotype as summarized in this chapter.  Strikingly, however, a defect in 
approximately one third of patients has either not been identified or subdivided into a 
specific group (Table 6.1).   
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6.3 Results  
 
6.3.1 Overall classification of the platelet defects 
Over the course of nearly 4 years, aggregation and ATP secretion were monitored in 80 
index patients with a bleeding tendency who are judged clinically to have a defect in 
platelet function. According to the patterns of abnormalities in aggregation and 
secretion, these patients were classified by the nature of their platelet defect into 5 
main groups as outlined in Table 6.1. Approximately two thirds of these patients in this 
study were found to have a platelet defect. The most common defects were those 
associated with dense granule secretion (21%), Gi signalling (19%) and TxA2 
formation/function (14%). The phenotype of patients with defects in Gi signaling and 
TxA2 formation/function were described in Chapters 4 and 5.  The pattern of response 
in the remaining groups of patients is summarized below.  
 
 
6.3.2 Secretion-like defect 
ATP secretion from platelet dense granules, measured using the luciferin/luciferase 
firely system, was analysed in all patients in order to investigate a possible storage pool 
defect. Accordingly, 21% of patients were found to have low or absent ATP secretion 
when compared with controls, a result that is consistent with the fact that storage pool 
disease is recognized to be a major cause of mild bleeding of platelet origin. 
Importantly, in all of these cases, the secretion defect was associated with a reduction 
in aggregation to low concentrations of all agonists, most notably collagen (not shown), 
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but with the exception of ADP as illustrated in a patient diagnosed with a new form of 
Hermansky-Pudlak syndrome, HPS-8, caused by mutation in the gene BLOC1-
S3/reduced pigmentation (Figure 6.1A).   This novel variant of HPS was identified by 
the group of Prof Eamonn Maher in a Birmingham family of Pakistan origin with a 
high level of consanguinity through autozygosity mapping (Morgan et al., 2006).  
Confirmation of the absence of dense granules in this patient was shown using 
transmission electron microscopy (Figure 6.1B).  Figure 6.2 shows the level of 
secretion observed to high concentrations PAR1 peptide and to CRP in the majority of 
patients diagnosed with a secretion disorder relative to controls.  In all cases, a 
significant decrease in secretion was seen to both the PAR1 peptide and to CRP, 
although the degree of the secretion defect varied between patients from approximately 
50% to complete abolition. 
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It is important to emphasis that a reduction in ATP secretion could be due to dense 
granule content deficiency (Holmsen and Weiss, 1972) or impaired secretion (Weiss 
and Rogers, 1972) which is considerably more common and could be caused by a 
defect in the signal transduction process or in the release machinery. These two 
conditions can be distinguished by measurement of platelet nucleotides, which is an 
assay that is performed in a limited number of platelet testing laboratories.  I measured 
nucleotides in two patients, one of them (Birm-JW-061006) had a reduction in the 
level of nucleotides (Figure 6.3) while the other was within the normal range. However, 
measurement of nucleotides was not performed as a routine part of my investigations 
as the major goal of this British Heart Foundation funded research was to identify 
patients with defects in the P2Y12 ADP receptor.   
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Storage pool disease refers to defects in secretion of dense or α-granules, or both sets 
of granules.  Defects in α-granule secretion, a condition known as Grey (or Gray) 
platelet syndrome, were not monitored in this study, as these would have been 
diagnosed by the testing laboratory through the characteristic ‘grey’ appearance of 
platelets on a blood smear as a consequence of loss of content and alteration in 
morphology.  However, α-granule defects that are not associated with this ‘grey’ 
appearance would have therefore been missed. 
 
6.3.3 GPVI-like defect  
Four of the eighty index cases were diagnosed with a GPVI-like defect on the basis of 
a selective defect in aggregation to the GPVI agonists, collagen and CRP, whereas the 
response to ADP, arachidonic acid and PAR1 and PAR4 peptides were within the 
normal range (Figure 6.4).  In view of the selective reduction in response to the two 
GPVI receptor agonists, I compared the ability of the snake venom toxin rhodocytin, 
which activates platelets through a similar pathway to that used by GPVI receptor but 
via a distinct receptor, CLEC-2 (Suzuki-Inoue et al., 2006), to activate the platelets. In 
three of these cases, a marked defect in response to rhodocytin was also observed as 
illustrated in Figure 6.5 suggesting a defect in the tyrosine kinase signaling cascade 
used by the two receptors.  In the other patient, described below, a selective loss of 
response to CRP and collagen was seen which is indicative of a defect at the level of 
the GPVI-FcR γ-chain complex.  
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The patient referred to above is a 62 yr old female, Sheff-MM-181207-01, who had a 
history of severe nosebleeds, one of which required hospital admission, easy bruising, 
excessive bleeding following dental extraction and heavy menstrual periods around 
menopause. Aggregation and secretion studies were performed and showed a right 
shift in the DRCs in response to CRP in comparison to the control, although full 
aggregation was elicited at a high concentration (Figure 6.6). In contrast, the 
rhodocytin response was similar, albeit slightly delayed, to the control at high and 
intermediate concentrations suggesting a possible defect at the GPVI receptor level.  A 
slightly reduced level of GPVI expression was detected in the patient relative to the 
control by western blotting where as similar levels were observed by flow cytometry 
(Figure 6.7).  These results although ruled out a quantitative defect in the GPVI 
receptor, they could not exclude dysfunctional defect in the receptor.  It is currently 
waiting to be sequenced.  
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6.3.4 Gq/13-like defect  
Two related patients (therefore one index case), brother and sister, from a non-
consanguineous relationship, were observed to have a partial defect in aggregation and 
secretion to agonists that signal through Gq and G13 heterotrimeric G proteins, namely 
PAR1 and PAR4 peptides and the TxA2 analogue U46619 (Figure 6.8). In contrast, the 
responses to ADP and CRP were only marginally inhibited arguing against a general 
defect in platelet activation. This is further supported by the similar nature of the 
response to the phorbol ester PMA in the patient’s platelets (Figure 6.8).  Potentially, 
the defect could be at the level of Gq or G13 although studies in mutant mice have 
shown that a defect in Gq gives rise to more pronounced inhibition of response similar 
to that observed in the two patients (Offermanns et al., 1997, Weig et al., 2008). 
The brother, 25 yrs old, had a history of excessive bleeding from childhood 
following tooth extraction (3 wisdom teeth) and with infrequent nose bleeds. The sister 
used to have heavy painful menstrual periods and more recently frequent nasal 
bleeding. Their mother also has a history of bleeding but was not available for 
investigation. Thus, it seems that that the two patients have inherited a dominant 
signalling defect in the Gq / G13-coupled receptor pathway, although this was not 
manifest at the level of protein kinase C as aggregation to phorbol myristate acetate 
(PMA), which directly activates protein kinase C, was similar to the control (Figure 
6.8). Further tests including calcium measurement will be essential to localise the 
defect.  
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6.3.5 Patients with a complex defect 
Two related patients (a father and a son) showed a wide range of platelet defects from 
early childhood indicating a dominant pattern of inheritence.  Defects included a 
marked decrease in the level of dense granules, reversible aggregation to ADP, loss of 
primary wave to adrenaline, loss of aggregation to GPVI, impaired aggregation to 
PAR4 and mild thrombocytopenia (not shown). It seems unlikely that all of these 
defects are brought about by a mutation in a single signalling protein suggesting a 
defect at the level of a transcription factor. One candidate is RUNX1, which is also 
associated with acute myeloid leukaemia (Ho et al., 1996, Sun et al., 2007).  The 
family declined the request to sequence the transcription factor.  
 
6.3.6 Patients with unknown defects 
In spite of a bleeding history and a clinical diagnosis of platelet dysfunction, no defect 
was detected in approximately one third of patients when investigated using 
lumiaggregometry.  It is possible that these patients do not have a defect in platelet 
function or that they have a defect that cannot be detected using this approach.  
Possible defects that could have been missed include a defect in procoagulant activity 
(Scott syndrome), defects in actin polymerization that only become manifest under 
shear, or defects in response to other platelet receptors such as CLEC-2.  The use of 
novel agents such as rhodocytin and further, more specialist tests are required in these 
patients to aid diagnosis. 
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6.4 Discussion 
 
The classification of platelet disorders on the basis of lumiaggregation results is a 
convenient way to subdivide patients and direct future gene sequencing projects.  Over 
the course of this thesis, I have had the opportunity to study 80 index cases of patients 
who have been clinically diagnosed with a platelet disorder.  This is a reasonable 
number on which to subdivide patients on the basis of their phenotype.  Strikingly, the 
most common defects were in granule secretion, Gi signaling and thromboxane 
function/formation, all of which are involved in the feedback activation of platelets.  In 
addition, four index cases were observed to have a GPVI-like defect and one a Gq/13-
like defect. The low frequency of the latter was surprising and may reflect the fact that 
most defects in this pathway cause more severe phenotypes in other tissues that cannot 
be tolerated.   
Interestingly, we were still unable to observe a defect in approximately one 
third of candidate patients using lumiaggregometry.  Additional platelet tests are 
required to investigate a possible defect in platelet activation by these agonists 
including the use of further agonists, measurement of aggregation under arteriolar rates 
of shear and procoagulant exposure.  It is also possible that the defect is not platelet in 
origin despite the clinical history being indicative of a platelet defect (e.g. it may be at 
the level of the vessel wall) or in the most mild of these cases, that the patients do not 
have a bleeding disorder.  Interestingly, we have not detected defects in the two PAR 
receptors throughout the course of this work despite the routine use of two PAR-
specific peptides thereby leaving open the question of whether a defect in one or both 
receptors will give rise to mild bleeding.  
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Overall, I believe that further development and refinement in aggregation testing 
and coanalysis of ATP secretion in combination with the measurement of other 
responses will be necessary to increase diagnosis of patients with mild, platelet-based 
bleeding disorders. This increase in testing will require extra resources, but in the long 
term will benefit both the patient and the clinic. 
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7.1 How should we test for patients with mild platelet-based bleeding disorder? 
 
 
A patient with a suspected platelet disorder is subject to a battery of preliminary tests 
which includes a full blood count, blood smear and assessment of platelet function. 
These tests will establish whether the platelet size, appearance and count are within the 
normal range. The absence of a gold-standard functional test means that platelet 
function studies vary between Institutions. Although there is a growing consensus 
against the bleeding time test, as it is invasive and poorly reproducible, it is still used in 
many centres today. In other cases, this has been replaced by a point-of-care test, such 
as the PFA-100, which measures time to occlusion following flow of whole blood at 
high shear over a cartridge of collagen/ADP or collagen/adrenaline. This test is not 
definitive for a platelet disorder, however, and in particular is influenced by the level 
of VWF which varies 2–3 fold in the normal population, and is reduced in patients 
with type 1 VWD, the most common form of bleeding disorder. As such, the value of 
the PFA-100 as an initial screen remains unproven (Hayward et al., 2006a).  
The most widely used test for platelet function is that of Born aggregometry which 
monitors light transmission through a suspension of platelets as aggregation proceeds. 
Among the advantages of this test its relative simplicity, the monitoring of responses to 
individual agonists and (in our experience) its reproducibility. Further, it can be 
combined with real-time monitoring of ATP secretion in a lumiaggregometer. The 
drawbacks of aggregation include the time taken to perform the assays and the fact that 
many investigators consider it to be unreliable and operator-dependent.  The 
interpretation of aggregation traces is also complex due to the feedback effects of ADP 
and TxA2, although this applies to nearly all tests of platelet function. These limitations 
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in current testing procedures can be minimised by standardisation of the light 
transmission aggregation and secretion assays as demonstrated by our work.  Further, 
in a recent study of 229 patients, light transmission aggregometry was standardized and 
validated to detect patients with platelet dysfunction (Hayward et al., 2009). The 
likelihood of diagnosing a bleeding disorder was significantly increased when maximal 
aggregation is reduced with two or more agonists (Hayward et al., 2009). 
 
Our approach of first defining the platelet phenotype through detailed laboratory 
analysis of the dose response relationships for nine platelet agonists provides important 
information on the defective pathway(s), and in some cases the defective protein, 
thereby allowing targetted genetic analysis. It is not practical for the clinical 
laboratories to follow this procedure because of the time taken for the analysis and also 
the relatively low number of patients that are referred to each Centre.  Nevertheless, a 
more limited analysis of platelet aggregation and secretion using one or two 
concentrations of the ‘standard’ platelets agonists (ADP, adrenaline, AA, collagen and 
ristocetin) is extremely valuable in aiding diagnosis as illustrated in the recent study by 
Hayward and colleagues (Hayward et al., 2009). Once a defect in platelet function is 
observed, referral to a specialized platelet laboratory is recommended to further aid 
diagnosis and thereby targetted genetic analysis.  The further testing can include an 
increased range of platelets agonists and more specialist tests, such as a measurement 
of second messengers (cAMP formation and Ca 2+ elevation), shear-based assay of 
platelet aggregation and flow cytometric measurements such as α-granule secretion.  
The sequencing of the genome and use of mass spectrometry in protein identification 
has lead recently to attempts to map the platelet transcriptosome and proteome, 
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respectively.  Neither of these goals however can be readily achieved because of the 
low level mRNA that is present in platelets, making contamination from other cells a 
major concern, and the very wide range of levels of protein expression found in 
platelets combined and the difficulty in identifying proteins that are expressed at low 
level (Watson et al., 2005). Further, neither of these ‘cataloguing’ approaches provides 
information on the functional roles of the platelet-expressed proteins.  An alternative 
approach to study gene and protein function that has been used by European Union 
funded Bloodomics consortium, headed by Dr Willem Ouwehand in Cambridge, is to 
perform genome-wide sequencing studies on patients with vascular disease.  These 
studies have concentrated on arterial thrombotic disorders because of their frequency 
rather than on platelet bleeding disorders which are both relatively rare and difficult to 
diagnose.  Further, by their very nature, these studies have not focused solely on 
platelet-expressed genes.  To date, a significant association has only been mapped to a 
single intronic sequence on chromosome 9 but the functional significance of this 
region of the chromosome is unknown (Consortium, 2007).  This surprisingly low 
success rate is believed to reflect the multifactorial nature of cardiovascular disease 
which is influenced by many factors governing life-style and diet. 
The use of genetic sequencing studies for identification of inherited mutations that give 
rise to mild platelet bleeding is in its infancy. Whole genome sequencing is extremely 
expensive even though costs are rapidly coming down. More importantly, the 
interpretation of whole genomes sequences requires sophisticated bioinformatics and 
patient controls (of the same ethnic population) to account for the large number of 
polymorphisms.  It is only in the case of sequence deletions or frame-shift mutations in 
platelet proteins of known function that a reasonable prediction of cause and effect be 
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made from whole genome sequencing.  Thus, at the present time, targeted sequencing 
as directed by platelet function studies offers the best way to identify mutations that 
give rise to platelet dysfunction.  This approach can either focus on a single candidate 
gene, as exemplified by my studies that lead to the identification of the homozygous 
base-pair shift mutation in the P2Y12 patient and the heterozygous mutation in the 
thromboxane receptor, or in the future, by focusing of groups of genes using second 
generation sequencers.  The latter approach will be essential for investigation of 
patients with suspected defects in signaling pathways due to the high number of 
candidate genes/proteins involved. 
 
7.2 Are platelet-based bleeding disorders under-recognised and multifactorial? 
 
Patients with a history of mild bleeding that is consistent with a platelet defect are 
considered to be extremely rare. It is my belief that this low frequency is in part due to 
limitations in diagnosis and the available methods of testing. Further, a mild platelet-
based bleeding disorder may often go undiagnosed for years, even to early adulthood, 
as the patient may not have received a sufficient number of haemostatic challenges. 
Indeed, many individuals with a mild platelet-based bleeding disorder will have a 
relatively normal life and may not even be aware of their increased bleeding tendency. 
A history of heavy bruising and frequent nose bleeds from childhood, on their own, are 
not sufficient for diagnosis as many unaffected individuals experience similar 
symptoms. Indeed, suspicion of a mild platelet disorder may not occur until a major 
trauma has occurred, such as invasive surgery (e.g. tooth removal) or childbirth, and 
the need for a blood transfusion. Diagnosis is further supported by the nature of the 
bleeding, with bleeding from mucous membranes being particularly common in 
 236
 
Chapter 7 – General Discussion 
platelet-based defects and by negative results for coagulation defects and VWD. A 
definitive diagnose is made through identification of a clear platelet functional defect 
in a functional study usually Born aggregometry. However, in many cases, diagnosis of 
a platelet disorder is based entirely on a clinical judgment and laboratory exclusion of 
other disorders. 
 
The complex signaling and feedback events that underlie platelet activation, and their 
apparent redundancy with each other, is one reason as to why investigation of 
aggregation may be insufficient to diagnose a platelet disorder. However, an additional 
explanation is that many platelet-based bleeding disorders are likely to be 
multifactorial and therefore caused by two or more inherited / acquired platelet defects.  
This is consistent with the fact that two of the genetic defects that have been found in 
patients studied during the course of this work, namely the K174E mutation in the 
P2Y12 receptor, and the thromboxane receptor defect, are heterozygous.  Further, four 
of the ten reported mutations in the P2Y12 receptor are heterozygous even though 
heterozygous family members exist alongside without an apparent history of bleeding.  
Moreover, the P2Y12-receptor antagonist clopidogrel is routinely prescribed to patients 
considered at risk of thrombosis with only a very low number experiencing an 
increased risk of bleeding. A similar story also exists for the cyclooxygenase / 
thromboxane pathway.  The mutation in the thromboxane receptor that I have reported 
is only the second to be identified and yet there are literally tens of millions of people 
worldwide who have taken non-steroidal anti-inflammatory agents such as aspirin 
without an apparent defect in bleeding and moreover the father of the patient, who has 
the same mutation, does not gave a history of bleeding.  Thus, it seems very likely that 
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the patients with the heterozygous defects in the P2Y12 and thromboxane receptors will 
have one or more further defects that underscore the increase in bleeding.  Indeed, in 
the case of the first P2Y12 patient, we believe this to be the case in that, for reasons 
unknown, only the nonfunctional allele of the P2Y12 receptor is expressed on the 
platelet surface (Hollopeter et al., 2001). Furthermore, the identification of the K174E 
mutation in a patient diagnosed with type 1 VWD is also consistent with the concept of 
the multifactorial nature of platelet-based bleeding disorders. Indeed, using the same 
approach that led to the identification of the K174E mutation through analysis of the 
EU funded MCMDM-1VWD cohort, we have identified two other heterozygous 
mutations in patients with type 1 VWDs, namely a P341A mutation in the P2Y12 ADP 
receptor and a L355F in the thrombin receptor.  The former mutation has been shown 
to interfere with receptor trafficking (Daly ME, 2009) while, as yet, we do not know 
the functional consequence of the thrombin receptor mutation.  The multifactorial 
model for platelet bleeding has important implications for patients who experience life-
threatening bleeding episodes while taking antiplatelet prophylactic medication for 
arterial thrombosis. 
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Appendix 1: 
APPENDICES 
CRP Cross-Linking 
Monomeric CRP (purchased from Dr. Richard Farndale (Cambridge University, UK) 
was dissolved in deionized water (11.1 mg/ml final concentration), and dialyzed using 
two dialyzing cells in 4 L deionized water at 4°C over night. In the following day, the 
CRP solutions was transferred from the dialyzing cells into 1.5 ml tubes and mixed 
with a prewarmed 1 M NaHCO3. Then 50 mM of the cross-linking reagent SPDP 
(succinimidyl 3-(-2-pyridyldithio)-propionate) that has been dissolved in a dry ethanol 
and prewarmed to 60 ○C was added, vortexed hard and blew off air with nitrogen gas 
then incubated at room temprature for almost exactly 1 hr. Finally, the CRP solution 
was dialysed twice, for 2 hr each, in 2 L of 0.01 M acetic acid per sample and stored at 
4°C. The activity of the XL-CRP were tested the next day in comparison with an old 
CRP batch as a control. A stock of 1.4 mg/ml of CRP was obtained. 
 
Appendix 2: 
 
Sequencing of P2RY12 gene:  
P2Y12 is encoded by sequence located entirely within exon 3 of P2RY12. The 
polymerase chain reaction (PCR) was used to amplify exon 3 (1480 bp), which 
includes 229 bp of 3’ untranslated region, and 137 bp of flanking intron 2 sequence, as 
three overlapping fragments (A, B and C) from the DNA of the index case. To 
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facilitate sequencing of amplified fragments with universal M13 primers, 
oligonucleotide primers were designed to incorporate universal M13-tails at the 5’ end. 
PCRs contained 30 ng of genomic DNA in a final volume of 15 µl of 1 x ReddyMix™ 
Master Mix (ABgene Ltd, Surrey, UK) containing 3 pmoles of each primer and either 
1.5 mM (fragments A and B)  or 3.0 mM (fragment C) MgCl2. Samples were 
denatured at 94°C for 7 minutes and then subjected to 35 cycles of denaturation at 
94°C for 1 minute, annealing for 1 minute at different temperatures depending on the 
fragment being amplified and extension at 72°C for 1 minute, followed by a final 
extension step at 72°C for 7 minutes. The amplified products were purified using 
ExoSAP-IT for PCR Product Clean Up (GE Healthcare, Amersham, UK) and 
sequenced on an automated ABI 3730 DNA capillary sequencer (ABI, Warrington, 
UK). DNA sequences were visualised using FinchTV software.  
 
Appendix 3: 
 
Binding of [3H]2MeS-ADP to platelets from a heterozygous carriers of the K174E 
mutation: 
The defect identified causes substitution of a positively charged lysine residue by a 
negatively charged glutamic acid residue at position 174 in the second extracellular 
loop of P2Y12, a region predicted to be required for ADP binding. The substitution of 
lysine 174 was therefore likely to cause inhibition of ADP binding (Costanzi et al., 
2004). Consistent with this, there was an up to 50% reduction in binding of [3H]2MeS-
ADP to the P2Y12 receptor (measured in the presence of the P2Y12 receptor antagonist, 
AR-C69931MX) on platelets from carriers of the K174E mutation, whereas binding to 
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P2Y1 (measured in the presence of the P2Y1 receptor antagonist, A3P5P) was similar to 
that observed on control platelets. This 50% reduction in binding of ligand to P2Y12 on 
platelets from a heterozygous carrier of the K174E defect is consistent with a complete 
abolition of binding to the mutated receptor.  
 
Appendix 4: 
 
Heterologous expression of wild-type and variant P2Y12 receptors: 
The partial P2Y12 defect associated with the K174E substitution was further 
investigated after introduction of the mutation into a HA-tagged P2Y12 expression 
construct, and stable expression of the wild-type and mutated P2Y12 receptor in CHO 
cells. The ability of the wild-type and K174E P2Y12 receptors to negatively couple to 
adenylyl cyclase was assessed by measurement of inhibition of forskolin-stimulated 
adenylyl cyclase activity. Forskolin-stimulated adenylyl cyclase activity was inhibited 
at all concentrations of ADP tested in cells stably expressing the wild-type receptor, 
with a maximal level of inhibition of 75%. In contrast, cells expressing the K174E 
variant showed defective ADP-dependent inhibition of forskolin-stimulated adenylyl 
cyclase activity with less than 20% inhibition observed at 10 µM ADP, a finding 
supporting a role for K174 in determining the ligand binding capacity of P2Y12 . Direct 
confirmation of the disruption in ligand binding to the K174E P2Y12 receptor stably 
expressed in CHO cells was demonstrated using [3H]2MeS-ADP. Binding to cells 
expressing the wild-type receptor was saturable and maximal at a ligand concentration 
of 1µM and the Kd was 0.31 ± 0.05 µM. In contrast, the K174E variant displayed 
approximately 30% of the ligand binding observed with the wild-type receptor using 
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concentrations of ligand up to 10µM indicating a defect in binding of ligand to the 
K174E variant, and explaining the absence of agonist-induced signalling in cells 
expressing the K174E variant.  
 
Appendix 5: 
 
RNA extraction and Reverse transcription of WBC RNA 
The buffy coats were extracted from centrifuged blood samples during platelet 
preparation for subsequent use in sequencing studies. 15ml of 1x RBC lysis buffer 
(1.5M NH4Cl, 10mM KHCO3, 1mM EDTA) was added and the sample rotated at 
0.12g for 15minutes on Stuart rotator (model SB3, Jencons PLS, UK.) The sample was 
then centrifuged at 380g for 5 minutes and the resulting red, transparent supernatant 
aspirated. Lysis steps were then repeated until a clean, white pellet was obtained with 
no obvious red blood cells present. The RNA was purified via chloroform extraction 
(200μl chloroform per 1ml Trizol) followed by isopropanol precipitation with 
incubation at -20oC for at least 1 hr. Following centrifugation at 18000g for 15 minutes 
at 4oC, the pellet was washed in ice-cold 75% v/v ethanol and dried at 50oC to allow all 
residual alcohol to evaporate. Finally, the pellet was resuspended in 20μl DEPC-treated 
nanopure water (dH2O- 0.1% DEPC), mixed and left to stand at room temperature 
(RT) for 10 minutes. Quantification of the RNA product was conducted using a 
Nanodrop spectrophotometer (model ND-1000, Labtech International, East Sussex, 
UK) to ensure sufficient yield had been obtained for use in subsequent assays. 
 
Synthesis of complementary DNA (cDNA) from white blood cell messenger RNA 
(mRNA) was performed using the First strand cDNA synthesis kit (Roche, UK) 
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according to the manufacturer’s protocol. The reaction mix comprised 2μg RNA, 3.2μg 
oligo (dT) primer, 40 units AMV reverse transcriptase, 100 units RNAse inhibitor, 
1mM dNTPs, 5mM MgCl, 1X reaction buffer (final concentration 10mM Tris HCl, 
50mM KCl, pH 8.3.) A negative control experiment was conducted in parallel with the 
RNA sample, where RNA was replaced by DEPC-treated nanopure water. The PCR 
reaction was conducted using peQlab PCR machine (advanced primus 25 model, 
Geneflow, UK) under the following conditions: 22oC for 10 minutes, 42oC for 60 
minutes, 90oC for 10 minutes and held at 4oC on completion. The resulting cDNA 
product was stored at –20oC. 
 
Appendix 6: 
 
Sequencing of TXA2R  gene 
Genomic DNA was purified from venous blood using the Nucleon DNA isolation kit 
(Tepnel Life Sciences, Manchester, UK). The entire coding sequence and splice donor 
and acceptor sites of TBXA2R (including α and β isoforms) were then amplified by 
PCR. Sequenced with a model 3700 DNA analyser using an ABI PRISM Big Dye V2 
reaction kit (Applied Biosystems, Foster City, CA, USA) and sequence variations were 
identified by comparison with the TBXA2R cDNA reference sequences NM_001060 
and NM_201636. The presence of the TBXA2R c. 910G>C transversion was confirmed 
by restriction analysis using AvaII. 
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Appendix 7: 
 
Binding of [3H]-SQ29548 to platelets from a heterozygous carriers of the D304N 
mutation: 
Platelets were isolated from PRP by centrifugation for 10 minutes at 1000g in the 
presence of 0.02 U/ml apyrase and prostaglandin E1 (140 nM). The pellet was 
resuspended in a modified Tyrode’s-HEPES buffer (145 mM NaCl, 2.9 mM KCl, 
10mM HEPES, 1 mM Mg Cl2 and 5mM glucose, pH 7.3) and  fixed with 4% 
formaldehyde. Platelets were then isolated by centrifugation and resuspended in 
binding buffer (20mM HEPES and 1mM MgCl2). Aliquots of platelet suspension were 
incubated with [3H]-SQ29548 (3 Ci/mmol, 0.01 to 0.1 μM) and specific binding was 
determined either in the presence or absence of unlabelled ligand (10 μM). After 
incubation for 20 minutes at room temperature, reactions were terminated by the 
addition of ice-cold binding buffer and rapid filtration through Whatman GF/C glass 
fiber filters under vacuum. Radioactivity bound to the filters was measured by 
scintillation counting . 
 
Appendix 8: 
 
TXA2R expression constructs, cell culture and transfections 
A pcDNA3.1 hygromycin expression vector containing the wild-type TXA2Rα cDNA 
fused at the N-terminus with the FLAG epitope tag was generated by standard cloning 
techniques. The variant p.D304N expression construct was then generated from this 
template by site-directed mutagenesis using a QuikChange® Site-directed Mutagenesis 
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Kit (Stratagene, Cambridge, UK) in accordance with the manufacturer’s instructions. 
The wild type and D304N expression constructs were then stably transfected into 
CHO-K1 cells. 
 
 
 
 
